

# BMJ Open

## Feasibility of a prospective multi-center prognostication study in critically ill patients with severe traumatic brain injury: The TBI-Prognosis pilot study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013779
Article Type:	Research
Date Submitted by the Author:	08-Aug-2016
Complete List of Authors:	<p>Turgeon, Alexis; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Lauzier, François; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Zarychanski, Ryan; University of Manitoba, Department of Internal Medicine, Sections of Critical Care Medicine and of Haematology/Medical Oncology</p> <p>Fergusson, Dean; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Leger, Caroline; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>McIntyre, Lauralyn; Ottawa Hospital Research Institute, Department of Critical Care Medicine; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Bernard, Francis ; Université de Montréal, Department of Medicine</p> <p>Rigamonti, Andrea; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Burns, Karen E. A.; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Griesdale, Donald; University of British Columbia, Department of Anesthesiology, Pharmacology &amp; Therapeutics</p> <p>Green, Robert; Dalhousie University, Department of Emergency Medicine</p> <p>Scales, Damon; University of Toronto, Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital</p> <p>Meade, Maureen; McMaster University, Department of Critical Care Medicine</p> <p>Savard, Martin; Université Laval, Department of Psychiatry and Neurosciences</p> <p>Shemilt, Michele; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>Paquet, Jérôme; Université Laval, Department of Surgery</p> <p>Gariépy, Jean-Luc; Université Laval, Department of Radiology and Nuclear Medicine</p> <p>Lavoie, André; Centre de Recherche du CHU de Québec - Université Laval,</p>

	Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine) Reddy, Kesh; McMaster University, Department of Critical Care Medicine Jichici, Draga; McMaster University, Department of Critical Care Medicine Pagliarello, Giuseppe; Ottawa Hospital Research Institute, Department of Critical Care Medicine Zygun, David; University of Alberta, Department of Critical Care Medicine Moore, Lynne; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Preventive and Social Medicine
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Epidemiology
Keywords:	Traumatic brain injury, Pilot study, Prognosis, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Outcome

SCHOLARONE™  
Manuscripts

## Feasibility of a prospective multi-center prognostication study in critically ill patients with severe traumatic brain injury: The TBI-Prognosis pilot study

Alexis F. Turgeon<sup>1,2</sup> MD MSc FRCPC, François Lauzier<sup>1,2</sup> MD MSc FRCPC, Ryan Zarychanski<sup>3</sup> MD MSc FRCPC, Dean A. Fergusson<sup>4</sup> PhD, Caroline Léger<sup>1</sup> PhD, Lauralyn A McIntyre<sup>4,5</sup> MD MSc FRCPC, Francis Bernard<sup>6</sup> MD FRCPC, Andrea Rigamonti<sup>7</sup> MD FRCPC, Karen Burns<sup>7</sup> MD MSc, Don Griesdale<sup>8</sup> MD MSc FRCPC, Robert Green<sup>9</sup> MD, Damon C Scales<sup>10</sup> MD PhD FRCPC, Maureen O. Meade<sup>11</sup> MD MSc FRCPC, Martin Savard<sup>12</sup> MD FRCPC, Michèle Shemilt<sup>1</sup> MSc, Jérôme Paquet<sup>13</sup> MD FRCPC, Jean-Luc Gariépy<sup>13</sup> MD FRCPC, André Lavoie<sup>1</sup> PhD, Kesh Reddy<sup>11</sup> MD FRCSC, Draga Jichici<sup>11</sup> MD FRCPC, Giuseppe Pagliarello<sup>5</sup> MD FRCPC, David Zygun<sup>14</sup> MD MSc FRCPC, Lynne Moore<sup>1,15</sup> PhD, for the TBI-Prognosis study team and the Canadian Critical Care Trials Group.

<sup>1</sup> Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma – Emergency – Critical Care Medicine), Québec City, Québec, Canada.

<sup>2</sup> Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Université Laval, Québec City, Québec, Canada.

<sup>3</sup> Department of Internal Medicine, Section of Critical Care and of Haematology and Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.

<sup>4</sup> Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit, Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

<sup>5</sup> Department of Critical Care Medicine, Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada.

<sup>6</sup> Department of Medicine, Université de Montréal, Montréal, Québec, Canada.

<sup>7</sup> Interdepartmental Division of Critical Care Medicine, St-Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

<sup>8</sup> Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia Vancouver, BC, Canada.

<sup>9</sup> Department of Emergency Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

<sup>10</sup> Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital, University of Toronto, Toronto, Ontario, Canada.

<sup>11</sup> Department of Critical Care Medicine, McMaster University, Hamilton, Ontario, Canada.

<sup>12</sup> Department of Psychiatry and Neurosciences, Université Laval, Québec, Québec, Canada.

<sup>13</sup> Department Radiology and Nuclear Medicine, Université Laval, Québec, Québec, Canada.

<sup>14</sup> Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada.

<sup>15</sup> Department of Preventive and Social Medicine, Université Laval, Québec, Québec, Canada.

**Corresponding author:**

Alexis F. Turgeon MD MSc FRCPC

CHU de Québec - Université Laval Research Center

Population Health and Optimal Health Practices Research Unit

(Trauma - Emergency - Critical Care Medicine)

1401, 18e rue, local H-037, Québec (Québec), G1J 1Z4

Phone: 418-649-0252 #66064

Email: alexis.turgeon@fmed.ulaval.ca

**Word Count: 2077**

**Keywords:** traumatic brain injury, prognosis, multicenter study, feasibility, pilot study

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0

**ABSTRACT** (298 words)

**Objective:** Severe traumatic brain injury is a significant cause of morbidity and mortality in young adults. Assessing long-term neurological outcome after such injury is difficult and often characterized by uncertainty. The objective of this pilot study was to establish the feasibility of conducting a large, multicenter prospective study to develop a prognostic model of long-term neurological outcome in critically ill patients with severe traumatic brain injury.

**Design:** Prospective cohort study.

**Setting:** Nine Canadian intensive care units enrolled patients suffering from acute severe traumatic brain injury. Clinical, biological, radiological and electrophysiological data were systematically collected during the first week in the intensive care unit. Mortality and functional outcome (Glasgow Outcome Scale extended) were assessed upon hospital discharge, and then 3, 6 and 12 months following injury.

**Outcomes:** The compliance to protocolized test procedures was the primary outcome. Secondary outcomes were enrolment rate and compliance to follow-up.

**Results:** We successfully enrolled 50 patients over a 12-month period. Most patients were male (80%), with a median age of 45 years (IQR 29.0 – 60.0), a median Injury Severity Score (ISS) of 38 (IQR 25-50), and a GCS of 6 (IQR 3-7). Mortality was 38% (19/50) and most deaths occurred following a decision to withdraw life-sustaining therapies (18/19). The main reasons for non-enrollment were the time window for inclusion being after regular working hours (35%, n=23) and oversight (24%, n=16). Compliance with protocolized test procedures ranged from 92% to 100% and enrolment rate was 43%. No patients were lost to follow-up at 6 months and 2 were at 12 months. The overall study adherence was 96%.

**Conclusion:** In this multicenter prospective pilot study, we achieved feasibility objectives pertaining to compliance to test, enrolment and follow-up. We conclude that the TBI-Prognosis prospective multicentre study in severe traumatic brain injury patients in Canada is feasible.

## STRENGTH AND LIMITATIONS OF THIS STUDY

- This pilot study involved 9 centers in 5 different provinces in Canada, thus showing the feasibility enrolling in different centers, health care systems and clinical settings.
- We enrolled in all centers but one due to start-up delay secondary to staffing issues.
- The sample size was large enough to allow testing a protocol of test procedures and to identify potential pitfalls to consider for the large scale study.

## INTRODUCTION

Severe traumatic brain injuries are catastrophic injuries primarily afflicting young individuals.[1] Mortality ranges from 30 to 50%, while 30% of survivors suffer from severe neurological sequelae.[2-5] Given the majority of victims are young with previous excellent quality of life, substantive human, social and financial repercussions are experienced by survivors.[6]

With regard to victims of severe traumatic brain injury, physicians and families often face important treatment decisions. They must decide to either undertake aggressive care in the hope of the patient will survive with an acceptable quality of life[7-10] or to withdraw life-sustaining therapy considering an unfavourable and undesirable prognosis. Serious concerns have been expressed regarding early decisions made to withdraw life-sustaining therapies in absence of evidence-based prognostic information.[11-13] Recently, we observed significant variations in mortality and in the incidence of withdrawal of life-sustaining therapies following severe traumatic brain injury in Canada.[8, 14] Current prognostic models are of limited clinical utility as they are based on data obtained from small[15-17], single centre[3, 16-22] retrospective studies[16, 21, 23-25] that did not consider secondary brain injury.[3, 16-20, 22, 23, 26-28] Consequently, it is not surprising to observe a wide variation in prognostic evaluation when surveying intensivists, neurosurgeons and neurologists caring for severe traumatic brain injury in Canada.[29] The development of appropriate prognosis tools and models is necessary to help guide the decision making process with families.

The objective of the TBI-Prognosis Pilot Study was to assess the feasibility of a conducting a large-scale, multicentre study to develop a prognostic model to inform long-term prognosis in patients with severe traumatic brain injury.



## METHODS

### Study design

We conducted a multicentre prospective pilot study in 9 level I trauma centres across Canada. Research Ethics Board approval was obtained from each participating center. Informed consent was obtained from surrogate decision makers prior to enrolment in most centers; deferred consent was permitted by Research Ethics Boards at two centers.

### Eligibility criteria

We included critically ill adults ( $\geq 18$  years of age) with severe traumatic brain injury (Glasgow coma scale (GCS)  $\leq 8$ ) due to blunt-force trauma on day 1 of intensive care unit admission. We excluded patients anticipated to be on mechanical ventilation for less than 48 hours, patients with solid malignancy associated with a life expectancy less than 12 months, liver cirrhosis Child C, chronic heart failure (NYHA class IV), end-stage chronic respiratory disease ( $O_2$  dependent), end-stage renal disease (chronic dialysis), previous neurologic disorder with abnormal findings on radiological imaging (CT-scan, magnetic resonance imaging (MRI)) or electrophysiological tests (electroencephalogram (EEG), somatosensory evoked potentials (SSEP)) or patients who were declared brain-dead when assessed for eligibility. Patients with no fixed address were also excluded due to difficulties in conducting follow-up.

### Data collection

Participants underwent a protocolized schedule of clinical, biological, radiological, and electrophysiological prognostic tests or examinations. Tests and examinations used in our study are, for the most part, commonly utilized in the care of patients with severe traumatic brain injury for diagnostic or prognostic purposes. Data were collected daily from intensive care unit admission until the 7<sup>th</sup> day following the injury, death or until hospital discharge, whichever came first. These included evaluation of serum glucose, complete blood count, creatinine and arterial

1  
2  
3 blood gases, pupillary reactivity, corneal reflex, episodes of increased intracranial hypertension  
4 (>25 mmHg), hypoxemia (arterial oxygen saturation of <90%) and hypotension (systolic blood  
5 pressure <90 mm Hg). A schedule of prognostic biological, radiological and electrophysiological  
6 tests/examinations was implemented (Figure 1). On intensive care unit day 1, 3 and 7, CT-  
7 scans were performed and blood samples were collected to measure serum biomarkers. These  
8 timelines were informed by a multicenter retrospective study and a health care survey of  
9 Canadian clinicians.[8, 29, 30] On intensive care unit day 7, MRI, SSEP and EEG examinations  
0 were performed. We permitted a time window of 24 hours (for CT-scan) and 48 hours (for MRI,  
1 SSEP and EEG) to reflect clinical practice and enhance feasibility over weekends.

### 2 Outcome measures

3 Our overarching objective of the research program is to develop a model to predict short  
4 (discharge), mid (3 months) and long-term neurological prognosis (6 and 12 months) in patients  
5 admitted to intensive care unit with severe traumatic brain injury. The functional outcome was  
6 evaluated using the Glasgow Outcome Scale extended (GOSe) (face to face (hospitalized  
7 patients) or phone interviews (discharged patients)).[31, 32] Our pilot study was designed to  
8 establish the feasibility of a large scale study adequately powered to develop prognostic models  
9 to help inform clinical decision-making. Our primary outcome was the compliance rate to the  
0 protocolized test procedures (tests performed or not performed). We considered a 90%  
1 compliance rate to be acceptable. Secondary outcomes were enrolment rate and compliance to  
2 follow-up. We also evaluated the percentage of potentially eligible patients that were excluded,  
3 the reasons for exclusion and adverse events related to the protocol.

### 4 Sample size

5 With a sample size of 50 patients we predicted to estimate a compliance to the scheduled test  
6 procedures of 90% with a margin of error of 10%.

## Statistical Analyses

Descriptive statistics were used to report the data. Data on compliance to the tests procedure, enrolment rate, compliance to follow-up and overall study adherence are presented using proportions. No comparative statistical testing was performed considering the pilot feasibility nature of this study.

## RESULTS

### Patient enrolment

Over a 12-month period totalising 208 weeks of active enrolment (all centers considered), participating centres screened 530 patients from which 116 were potentially eligible and 50 were enrolled (43%). The two main reasons for non-enrolment were the time-window for inclusion being after regular working hours and personnel oversight (Figure 2). We observed few refusals from surrogate decision makers and physicians, as well as non-enrolment due to the absence of a surrogate decision maker. No patient, once included in the study, was excluded. One center did not succeed to implement the study due to staffing issues and did not contribute any patients to this pilot trial. The majority of recruitment (32 patients, 64%) took place during weekdays; three of the centers enrolled patients on weekends. Informed consent was mostly obtained (41 patients, 82%) between 9:00 am and 6:00 pm.

### Patient characteristics

The median age of participants was 45 years (Interquartile range (IQR), 29 – 60 years) and 80% were male (40 patients, 80%). The median GCS at intensive care unit admission was 6 (IQR: 3-7) while the Injury Severity Score (ISS) was 38 (IQR 25-50) (Table 1). In 88% of patients, traumatic brain injury occurred following motor vehicle collision (MVC) or fall.

**Table 1. Patients demographic**

Characteristics	Patients (n=50)
Age (median, IQR)	45 (29 – 60)
Male (n, %)	40 (80%)
GCS in ER (median, IQR)	6 (3 - 7)
APACHE II score (mean $\pm$ SD)	20.2 $\pm$ 6.84
ISS score (median, IQR)	38 (25 - 30)
Absent pupillary reactivity (ICU day 1)	36 (72%)
Absent corneal reflex (ICU day 1)	7 (14%)
<b>Cause of trauma (n, %)</b>	
MVC-occupant	21 (42%)
MVC-motorcyclist	9 (18%)
MVC-pedestrian	2 (4%)
Fall	14 (28%)
Assault	2 (4%)
Other	2 (4%)

IQR: Interquartile range; GCS: Glasgow Coma Scale; ER: Emergency room; MVC: Motor vehicle collision SD: Standard Deviation; APACHE: Acute Physiology and Chronic Health Evaluation; ISS: Injury Severity Score, ICU: Intensive care unit

### Compliance to test procedures

The compliance to the protocol of test procedures ranged from 92% to 100%, depending on the test performed. Compliance to tests was measured according to the survival status during the time window in which the test was scheduled (Figure 3). We observed 94% compliance for SSEP (3 missed tests), 96% for EEG (2 missed tests), and 92% for MRI (4 missed tests). Day 7 MRI was delayed for 20% (n=10) of the patients, most of them (n=6) due to the presence of

1  
2  
3 material incompatible with the performance of the MRI procedure. No CT-scans were missed on  
4  
5 day 1 and 3, while the compliance for day 7 CT-scans was 96% (2 missed scans). All but one  
6  
7 blood sample were collected. The main reason for not conducting a specific test was a change  
8  
9 in level of care (palliative care). The main explanation for performing tests outside of the time  
0  
1 window was patient instability (hemodynamic or increased intracranial pressure). We observed  
2  
3 no adverse events related to this study and tests performed.  
4  
5  
6

### 7 8 **Follow-up measures**

9  
0 Two patients were lost to follow-up at 12 months, but none were at 6 months. Overall, 33  
1  
2 patients (66%) had an unfavourable outcome at 12 months (GOSe 1-4). Mortality was 38%  
3  
4 (19/50) and most deaths were associated with a decision to withdraw life-sustaining therapies  
5  
6 (18/19). No patient died during follow-up after hospital discharge.  
7  
8  
9

### 0 1 2 3 **INTERPRETATION**

4  
5 In this multicenter prospective pilot feasibility study, we achieved high compliance with the study  
6  
7 procedures, an acceptable enrolment rate and had a low rate of loss to follow-up. All except one  
8  
9 center achieved acceptable enrolment during the study period. The lessons learned during this  
0  
1 multicenter pilot prospective study have informed the design of the TBI-Prognosis multicenter  
2  
3 prospective study (NCT02452541), which is currently ongoing.  
4  
5  
6

7  
8 The high compliance rate to the test procedures observed in our study is a paramount result for  
9  
0 the feasibility of the large scale study. Several reasons may explain this high compliance. First,  
1  
2 our protocol is straightforward and mainly relies on reminders for timely test procedures. Second,  
3  
4 the uniformity of the tests and the flexibility of test timing allow these tests to be included  
5  
6 seamlessly into the patient's care continuum. Third, adherence to the test schedule has also  
7  
8  
9  
0



1  
2  
3 participate in the shared decision-making consent process.[41, 42] Indeed, the two centers that  
4  
5 implemented this method recruited a greater number of patients than the other sites in  
6  
7 accordance with the duration of the screening period. Strategies for approaching families in time  
8  
9 of stress were also discussed.[37] With much preparatory work completed, the TBI-Prognosis  
0  
1 team and the Canadian Critical Care Trials Group are now undertaking the large multicenter  
2  
3 prospective cohort study informed by the results of this pilot feasibility study.  
4  
5  
6  
7  
8

9  
0 In this multicenter prospective pilot study, we successfully enrolled participants following an  
1  
2 acceptable enrolment rate, reached our targeted sample size, achieved feasibility objectives  
3  
4 pertaining to the compliance to the test procedures, compliance to follow-up, as well as the  
5  
6 overall adherence the study protocol. We conclude that a prospective multicentre study in  
7  
8 severe traumatic brain injury patients in Canada aiming at developing a prognostic model in the  
9  
0 acute phase of care is feasible.  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0

## ACKNOWLEDGMENTS

We would like to acknowledge Ramona-Florina Fratu for her help in the statistical analyses, as well as Catherine Ouellet for assembling the data. We are grateful to members of the Canadian Critical Care Trials Group (CCCTG) for their support and guidance, and for CCCTG Grants and Manuscript Committee and Paule Lessard Bonaventure for the critical review of this manuscript. The authors also thank all the research coordinators and research professionals who were involved with this study for their help and dedication.

## CONTRIBUTIONS

AFT, FL, RZ, DAF, LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, JP, JLG, AL, KR, GP, DZ and LM were involved in conception and design. AFT, FL, RZ, DAF, CL, LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were involved in the acquisition and interpretation of data. AFT, CL and MSh drafted the manuscript. AFT, FL, RZ, DAF, CL, LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were involved in revising the manuscript and approved the version published.

## COMPETING INTERESTS

The authors declared no competing interests.

## FUNDING AND FINANCIAL DISCLOSURE

This study was funded by the Fonds de la Recherche du Québec - Santé (FRQS) (grant #5888) and the Canadian Intensive Care Foundation (CICF). Drs Moore, McIntyre, Turgeon and Zarychanski are recipients of New Investigator Awards from the Canadian Institutes of Health Research (CIHR). Dr Turgeon and Lauzier are supported by the Traumatology Research Consortium of the FRQS. Dr Lauzier is a recipient of a salary support Award from the FRQS. The authors have no conflict of interest to declare.

## DATA SHARING

There are no additional unpublished data available.



## REFERENCES

1. National Scientific Advisory Committee. Identifying priorities for research and capacity development in injury as a multi-insitute strategic initiative within the Canadian Institutes of Health Research. In: Listening for Direction on Injury: final report. Canada: Instituts canadiens de recherche en santé, 2004.
2. Medical aspects of the persistent vegetative state. The Multi-Society Task Force on PVS. *N Engl J Med* 1994;330:1499-508.
3. Lannoo E, Van Rietvelde F, Colardyn F, et al. Early predictors of mortality and morbidity after severe closed head injury. *J Neurotrauma* 2000;17:403-14.
4. Levati A, Farina ML, Vecchi G, et al. Prognosis of severe head injuries. *J Neurosurg* 1982;57:779-83.
5. Zygun DA, Laupland KB, Hader WJ, et al. Severe traumatic brain injury in a large Canadian health region. *Can J Neurol Sci* 2005;32:87-92.
6. Meerding WJ, Mulder S, van Beeck EF. Incidence and costs of injuries in The Netherlands. *Eur J Public Health* 2006;16:272-8.
7. Kramer AH, Zygun DA. Neurocritical care: why does it make a difference? *Curr Opin Crit Care* 2014;20:174-81.
8. Turgeon AF, Lauzier F, Simard JF, et al. Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study. *CMAJ* 2011;183:1581-8.
9. van Beinum A, Hornby L, Ramsay T, et al. Exploration of Withdrawal of Life-Sustaining Therapy in Canadian Intensive Care Units. *J Intensive Care Med* 2016;31:243-51.
10. Huynh TN, Walling AM, Le TX, et al. Factors associated with palliative withdrawal of mechanical ventilation and time to death after withdrawal. *J Palliat Med* 2013;16:1368-74.

- 1  
2  
3 11. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage  
4  
5 may lead to self-fulfilling prophecies. *Neurology* 2001;56:766-72.  
6
- 7  
8 12. Mayer SA, Kossoff SB. Withdrawal of life support in the neurological intensive care unit.  
9  
0 *Neurology* 1999;52:1602-9.  
1
- 2  
3 13. O'Callahan JG, Fink C, Pitts LH, et al. Withholding and withdrawing of life support from  
4  
5 patients with severe head injury. *Crit Care Med* 1995;23:1567-75.  
6
- 7  
8 14. Cote N, Turgeon AF, Lauzier F, et al. Factors associated with the withdrawal of life-  
9  
0 sustaining therapies in patients with severe traumatic brain injury: a multicenter cohort  
1  
2 study. *Neurocrit Care* 2013;18:154-60.  
2  
3
- 4  
5 15. Brain Trauma Foundation, American Association of Neurological Surgeons, Joint section on  
6  
7 neurotrauma and critical care. *Management and prognosis of severe traumatic brain*  
8  
9 *injury*. New York, USA: Brain Trauma Foundation, 2000.  
0
- 1  
2 16. Lai YC, Chen FG, Goh MH, et al. Predictors of long-term outcome in severe head injury.  
3  
4 *Ann Acad Med Singapore* 1998;27:326-31.  
5
- 6  
7 17. Rovlias A, Kotsou S. Classification and regression tree for prediction of outcome after  
8  
9 severe head injury using simple clinical and laboratory variables. *J Neurotrauma*  
0  
1 2004;21:886-93.  
2
- 3  
4 18. Andrews PJ, Sleeman DH, Statham PF, et al. Predicting recovery in patients suffering from  
5  
6 traumatic brain injury by using admission variables and physiological data: a comparison  
7  
8 between decision tree analysis and logistic regression. *J Neurosurg* 2002;97:326-36.  
9
- 0  
1 19. Demetriades D, Kuncir E, Velmahos GC, et al. Outcome and prognostic factors in head  
2  
3 injuries with an admission Glasgow Coma Scale score of 3. *Arch Surg* 2004;139:1066-8.  
4
- 5  
6 20. Fearnside MR, Cook RJ, McDougall P, et al. The Westmead Head Injury Project outcome in  
7  
8 severe head injury. A comparative analysis of pre-hospital, clinical and CT variables. *Br J*  
9  
0 *Neurosurg* 1993;7:267-79.  
1



- 1  
2  
3 31. Jennett B, Bond MR. Assessment of outcome after severe brain damage. *Lancet*  
4  
5 1975;1:480-4.  
6
- 7  
8 32. Jennett B, Snoek J, Bond M, et al. Disability after severe head injury: observations on the  
9  
0 use of the Glasgow Outcome Scale. *J Neurol Neurosurg Psychiatry* 1981;44:285-93.  
1
- 2  
3 33. Tyson SF, Thomas N, Vail A, et al. Recruiting to inpatient-based rehabilitation trials: lessons  
4  
5 learned. *Trials* 2015;16:588.  
6
- 7  
8 34. Fletcher B, Gheorghe A, Moore D, et al. Improving the recruitment activity of clinicians in  
9  
0 randomised controlled trials: a systematic review. *BMJ open* 2012;2:e000496.  
1
- 2  
2 35. Dickson S, Logan J, Hagen S, et al. Reflecting on the methodological challenges of  
3  
4 recruiting to a United Kingdom-wide, multi-centre, randomised controlled trial in  
5  
6 gynaecology outpatient settings. *Trials* 2013;14:389.  
7
- 8  
9 36. Blanton S, Morris DM, Prettyman MG, et al. Lessons learned in participant recruitment and  
0  
1 retention: the EXCITE trial. *Phys Ther* 2006;86:1520-33.  
2
- 3  
3 37. Gardner G, Gardner A, MacLellan L, et al. Reconceptualising the objectives of a pilot study  
4  
5 for clinical research. *Int J Nurs Stud* 2003;40:719-24.  
6
- 7  
8 38. McIntyre LA, Fergusson D, Cook DJ, et al. Fluid resuscitation in the management of early  
9  
0 septic shock (FINESS): a randomized controlled feasibility trial. *Can J Anaesth*  
1  
2 2008;55:819-26.  
3
- 4  
5 39. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after  
6  
7 Traumatic Brain Injury. *N Engl J Med* 2015;373:2403-12.  
8
- 9  
0 40. Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for  
1  
2 acute traumatic brain injury. *N Engl J Med* 2014;371:2457-66.  
3
- 4  
5 41. Potter JE, McKinley S, Delaney A. Research participants' opinions of delayed consent for a  
6  
7 randomised controlled trial of glucose control in intensive care. *Intensive care medicine*  
8  
9 2013;39:472-80.  
0

- 1  
2  
3 42. Gamble C, Nadel S, Snape D, et al. What parents of children who have received emergency  
4 care think about deferring consent in randomised trials of emergency treatments: postal  
5 survey. *PloS one* 2012;7:e35982.  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0  
1  
2  
3  
4  
5  
6  
7  
8  
9  
0

For peer review only

**Figure 1. TBI-Prognosis test schedule.**

The arrows indicate the prescribed time frame to perform tests or take blood samples. The study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7. The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before or after the seventh day.

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

**Figure 2. Reasons for non-enrolment**

SDM: Shared Decision Making

**Figure 3. Compliance to the scheduled test procedures**

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

	ICU Day 1	ICU Day 2	ICU Day 3	ICU Day 4	ICU Day 5	ICU Day 6	ICU Day 7	ICU Day 8	ICU Day 9
CT-scan (+/- 24 hrs)	←→			←→			←→		
Blood samples (biomarkers)	←→		←→				←→		
EEG, SSEP, MRI (+/- 48 hrs)					←→				


**Figure 1. TBI-Prognosis test schedule.**

The arrows indicate the prescribed time frame to perform tests or take blood samples. The study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7. The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before or after the seventh day.

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials







**Figure 3. Compliance to the scheduled test procedures**

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram;  
ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP:  
Somatosensory Evoked Potentials

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,8, Figure 1
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	Part of pilot goal
		(d) If applicable, explain how loss to follow-up was addressed	Part of pilot goal
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9, Figure 2
		(c) Consider use of a flow diagram	No
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	10, 11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	9, 10, 11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9, 10, 11
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11, 12
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	5, 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12, 13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Prognostication in critically ill patients with severe traumatic brain injury: The TBI-Prognosis multicenter feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013779.R1
Article Type:	Research
Date Submitted by the Author:	03-Dec-2016
Complete List of Authors:	<p>Turgeon, Alexis; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Lauzier, François; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Zarychanski, Ryan; University of Manitoba, Department of Internal Medicine, Sections of Critical Care Medicine and of Haematology/Medical Oncology</p> <p>Fergusson, Dean; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Leger, Caroline; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>McIntyre, Lauralyn; Ottawa Hospital Research Institute, Department of Critical Care Medicine; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Bernard, Francis ; Université de Montréal, Department of Medicine</p> <p>Rigamonti, Andrea; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Burns, Karen E. A.; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Griesdale, Donald; University of British Columbia, Department of Anesthesiology, Pharmacology &amp; Therapeutics</p> <p>Green, Robert; Dalhousie University, Department of Emergency Medicine</p> <p>Scales, Damon; University of Toronto, Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital</p> <p>Meade, Maureen; McMaster University, Department of Critical Care Medicine</p> <p>Savard, Martin; Université Laval, Department of Psychiatry and Neurosciences</p> <p>Shemilt, Michele; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>Paquet, Jérôme; Université Laval, Department of Surgery</p> <p>Gariépy, Jean-Luc; Université Laval, Department of Radiology and Nuclear Medicine</p> <p>Lavoie, André; Centre de Recherche du CHU de Québec - Université Laval,</p>

	Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine) Reddy, Kesh; McMaster University, Department of Critical Care Medicine Jichici, Draga; McMaster University, Department of Critical Care Medicine Pagliarello, Giuseppe; Ottawa Hospital Research Institute, Department of Critical Care Medicine Zygun, David; University of Alberta, Department of Critical Care Medicine Moore, Lynne; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Preventive and Social Medicine
<b>Primary Subject Heading</b> :	Intensive care
<b>Secondary Subject Heading</b> :	Epidemiology
<b>Keywords</b> :	Traumatic brain injury, Pilot study, Prognosis, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Outcome

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Prognostication in critically ill patients with severe traumatic brain injury:**  
5  
6 **The TBI-Prognosis multicenter feasibility study**  
7  
8  
9

10  
11  
12  
13 Alexis F. Turgeon<sup>1,2</sup> MD MSc FRCPC, François Lauzier<sup>1,2</sup> MD MSc FRCPC, Ryan Zarychanski<sup>3</sup>  
14 MD MSc FRCPC, Dean A. Fergusson<sup>4</sup> PhD, Caroline Léger<sup>1</sup> PhD, Lauralyn A McIntyre<sup>4,5</sup> MD  
15 MSc FRCPC, Francis Bernard<sup>6</sup> MD FRCPC, Andrea Rigamonti<sup>7</sup> MD FRCPC, Karen Burns<sup>7</sup> MD  
16 MSc, Don Griesdale<sup>8</sup> MD MSc FRCPC, Robert Green<sup>9</sup> MD, Damon C Scales<sup>10</sup> MD PhD  
17 FRCPC, Maureen O. Meade<sup>11</sup> MD MSc FRCPC, Martin Savard<sup>12</sup> MD FRCPC, Michèle Shemilt<sup>1</sup>  
18 MSc, Jérôme Paquet<sup>13</sup> MD FRCPC, Jean-Luc Gariépy<sup>13</sup> MD FRCPC, André Lavoie<sup>1</sup> PhD, Kesh  
19 Reddy<sup>11</sup> MD FRCSC, Draga Jichici<sup>11</sup> MD FRCPC, Giuseppe Pagliarello<sup>5</sup> MD FRCPC, David  
20 Zygun<sup>14</sup> MD MSc FRCPC, Lynne Moore<sup>1,15</sup> PhD, for the TBI-Prognosis study team and the  
21 Canadian Critical Care Trials Group.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 <sup>1</sup> Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal  
39 Health Practices Research Unit (Trauma – Emergency – Critical Care Medicine), Québec City,  
40 Québec, Canada.  
41  
42  
43

44 <sup>2</sup> Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine,  
45 Université Laval, Québec City, Québec, Canada.  
46  
47  
48

49 <sup>3</sup> Department of Internal Medicine, Section of Critical Care and of Haematology and Medical  
50 Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.  
51  
52  
53

54 <sup>4</sup> Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit, Ottawa Health  
55 Research Institute, University of Ottawa, Ottawa, Ontario, Canada.  
56  
57  
58  
59  
60

1  
2  
3 <sup>5</sup> Department of Critical Care Medicine, Ottawa Hospital, University of Ottawa, Ottawa, Ontario,  
4  
5 Canada.

6  
7 <sup>6</sup> Department of Medicine, Université de Montréal, Montréal, Québec, Canada.

8  
9  
10 <sup>7</sup> Interdepartmental Division of Critical Care Medicine, St-Michael's Hospital, University of  
11  
12 Toronto, Toronto, Ontario, Canada.

13  
14 <sup>8</sup> Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia  
15  
16 Vancouver, BC, Canada.

17  
18  
19 <sup>9</sup> Department of Emergency Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

20  
21  
22 <sup>10</sup> Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital, University of  
23  
24 Toronto, Toronto, Ontario, Canada.

25  
26  
27 <sup>11</sup> Department of Critical Care Medicine, McMaster University, Hamilton, Ontario, Canada.

28  
29 <sup>12</sup> Department of Psychiatry and Neurosciences, Université Laval, Québec, Québec, Canada.

30  
31 <sup>13</sup> Department Radiology and Nuclear Medicine, Université Laval, Québec, Québec, Canada.

32  
33  
34 <sup>14</sup> Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada.

35  
36  
37 <sup>15</sup> Department of Preventive and Social Medicine, Université Laval, Québec, Québec, Canada.

38  
39 **Corresponding author:**

40  
41 Alexis F. Turgeon MD MSc FRCPC

42  
43 CHU de Québec - Université Laval Research Center

44  
45 Population Health and Optimal Health Practices Research Unit

46  
47 (Trauma - Emergency - Critical Care Medicine)

48  
49 1401, 18e rue, local H-037, Québec (Québec), G1J 1Z4

50  
51 Phone: 418-649-0252 #66064

52  
53 Email: alexis.turgeon@fmed.ulaval.ca

54  
55  
56  
57  
58 **Word Count: 2885**

1  
2  
3  
4  
5 **Keywords:** traumatic brain injury, prognosis, multicenter study, feasibility, feasibility study  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**ABSTRACT** (292 words)

**Objective:** Severe traumatic brain injury is a significant cause of morbidity and mortality in young adults. Assessing long-term neurological outcome after such injury is difficult and often characterized by uncertainty. The objective of this feasibility study was to establish the feasibility of conducting a large, multicenter prospective study to develop a prognostic model of long-term neurological outcome in critically ill patients with severe traumatic brain injury.

**Design:** Prospective cohort study.

**Setting:** Nine Canadian intensive care units enrolled patients suffering from acute severe traumatic brain injury. Clinical, biological, radiological and electrophysiological data were systematically collected during the first week in the intensive care unit. Mortality and functional outcome (Glasgow Outcome Scale extended) were assessed upon hospital discharge, and then 3, 6 and 12 months following injury.

**Outcomes:** The compliance to protocolized test procedures was the primary outcome. Secondary outcomes were enrolment rate and compliance to follow-up.

**Results:** We successfully enrolled 50 patients over a 12-month period. Most patients were male (80%), with a median age of 45 years (IQR 29.0 – 60.0), a median Injury Severity Score (ISS) of 38 (IQR 25-50), and a GCS of 6 (IQR 3-7). Mortality was 38% (19/50) and most deaths occurred following a decision to withdraw life-sustaining therapies (18/19). The main reasons for non-enrollment were the time window for inclusion being after regular working hours (35%, n=23) and oversight (24%, n=16). Compliance with protocolized test procedures ranged from 92% to 100% and enrolment rate was 43%. No patients were lost to follow-up at 6 months and 2 were at 12 months.

**Conclusion:** In this multicenter prospective feasibility study, we achieved feasibility objectives pertaining to compliance to test, enrolment and follow-up. We conclude that the TBI-Prognosis prospective multicentre study in severe traumatic brain injury patients in Canada is feasible.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Our study involved nine centers in five different provinces in Canada and showed the feasibility of enrolling critically ill patients with severe traumatic brain injury and assess 12-months outcome measures.
- Our study sample size allowed testing a protocol of test procedures and identifying potential pitfalls to consider for a large-scale prognostic study.
- Some eligible patients were missed due to an admission to the intensive care unit outside of working hours or were oversight by the research personnel.

## INTRODUCTION

Severe traumatic brain injuries are catastrophic injuries primarily afflicting young individuals.[1] Mortality ranges from 30 to 50%, while 30% of survivors suffer from severe neurological sequelae.[2-5] Given the majority of victims are young with previous excellent quality of life, substantive human, social and financial repercussions are experienced by survivors.[6]

With regard to victims of severe traumatic brain injury, physicians and families often face important treatment decisions. They must decide to either undertake aggressive care in the hope of the patient will survive with an acceptable quality of life[7-10] or to withdraw life-sustaining therapy considering an unfavourable and undesirable prognosis. Serious concerns have been expressed regarding early decisions made to withdraw life-sustaining therapies in absence of evidence-based prognostic information.[11-14] Recently, we observed significant variations in mortality and in the incidence of withdrawal of life-sustaining therapies following severe traumatic brain injury in Canada.[8, 15] Current prognostic models are of limited clinical utility as they are based on data obtained from small[16-18], single centre[3, 17-23] retrospective studies[17, 22, 24-26] that did not consider secondary brain injury.[3, 17-21, 23, 24, 27-28] Consequently, it is not surprising to observe a wide variation in prognostic evaluation when surveying intensivists, neurosurgeons and neurologists caring for severe traumatic brain injury in Canada.[29] The development of appropriate prognosis tools and models is necessary to help guide the decision making process with families.

The objective of the TBI-Prognosis Feasibility Study was to assess the feasibility of a conducting a large-scale, multicentre study to develop a prognostic model to inform long-term prognosis in patients with severe traumatic brain injury. The study was conducted in the

1  
2  
3 Canadian health care system in which trauma, neurosurgery and critical care are part of a public  
4  
5 system with universal health care coverage for all citizens.  
6  
7  
8  
9

## 10 **METHODS**

### 11 **Study design**

12  
13  
14 We conducted a multicentre prospective feasibility study in 9 level I trauma centres across  
15  
16 Canada. Research Ethics Board approval was obtained from each participating center. Informed  
17  
18 consent was obtained from surrogate decision makers prior to enrolment in most centers;  
19  
20 deferred consent was permitted by Research Ethics Boards at two centers. This study was  
21  
22 conducted  
23  
24  
25  
26  
27

### 28 **Eligibility criteria**

29  
30 We included critically ill adults ( $\geq 18$  years of age) with severe traumatic brain injury (Glasgow  
31  
32 coma scale (GCS)  $\leq 8$  following resuscitation) due to blunt-force trauma on day 1 of intensive  
33  
34 care unit admission. We excluded patients anticipated to be on mechanical ventilation for less  
35  
36 than 48 hours, patients with solid malignancy associated with a life expectancy less than 12  
37  
38 months, liver cirrhosis Child C, chronic heart failure (NYHA class IV), end-stage chronic  
39  
40 respiratory disease ( $O_2$  dependent), end-stage renal disease (chronic dialysis), previous  
41  
42 neurologic disorder with abnormal findings on radiological imaging (CT-scan, magnetic  
43  
44 resonance imaging (MRI)) or electrophysiological tests (electroencephalogram (EEG),  
45  
46 somatosensory evoked potentials (SSEP)) or patients who were declared brain-dead when  
47  
48 assessed for eligibility. Patients with no fixed address were also excluded due to difficulties in  
49  
50 conducting follow-up.  
51  
52  
53  
54  
55  
56

### 57 **Data collection**

1  
2  
3 Participants underwent a protocolized schedule of clinical, biological, radiological, and  
4  
5 electrophysiological prognostic tests or examinations. Tests and examinations used in our study  
6  
7 were commonly utilized in the care of patients with severe traumatic brain injury for diagnostic or  
8  
9 prognostic purposes except for blood samples. Data were collected daily from intensive care  
10  
11 unit admission until the 7<sup>th</sup> day following the injury, death or until hospital discharge, whichever  
12  
13 came first. These included pupillary reactivity, corneal reflex, GCS, episodes of increased  
14  
15 intracranial hypertension (>25 mmHg), hypoxemia (arterial oxygen saturation of <90%) and  
16  
17 hypotension (systolic blood pressure <90 mm Hg). Data was prospectively collected at the  
18  
19 bedside using specific case report forms. We also collected serum glucose (highest and lowest  
20  
21 value), complete blood count, INR, prothrombin time, sodium, creatinine, arterial blood gases,  
22  
23 also on a daily basis if the data was available as per clinical decision by the medical team. A  
24  
25 schedule of prognostic biological, radiological and electrophysiological tests/examinations was  
26  
27 implemented (Figure 1). On intensive care unit day 1, 3 and 7, CT-scans were performed and  
28  
29 blood samples were collected to measure serum biomarkers. These timelines were informed by  
30  
31 a multicenter retrospective study and a health care survey of Canadian clinicians.[8, 29, 30] On  
32  
33 intensive care unit day 7, MRI, SSEP and EEG examinations were performed. We permitted a  
34  
35 time window of 24 hours (for CT-scan) and 48 hours (for MRI, SSEP and EEG) to reflect clinical  
36  
37 practice and enhance feasibility over weekends.  
38  
39  
40  
41  
42  
43  
44

### 45 **Outcome measures**

46  
47 Our overarching objective of the research program is to develop a model to predict short  
48  
49 (discharge), mid (3 months) and long-term neurological prognosis (6 and 12 months) in patients  
50  
51 admitted to intensive care unit with severe traumatic brain injury. The functional outcome was  
52  
53 evaluated using the Glasgow Outcome Scale extended (GOSe) (face to face (hospitalized  
54  
55 patients) or phone interviews (discharged patients)).[31, 32] Our feasibility study was designed  
56  
57 to establish the feasibility of a large scale study adequately powered to develop prognostic  
58  
59  
60

1  
2  
3 models to help inform clinical decision-making. Our primary outcome was the compliance rate to  
4  
5 the protocolized test procedures (tests performed or not performed). We considered a 90%  
6  
7 compliance rate to be acceptable. Secondary outcomes were enrolment rate and compliance to  
8  
9 follow-up. We also evaluated the percentage of potentially eligible patients that were excluded,  
10  
11 the reasons for exclusion and adverse events related to the protocol.  
12  
13

### 14 **Research team at participating centers**

15  
16 At each participating center, a research coordinator and/or research nurse, was involved in the  
17  
18 implementation of the study in the intensive care unit, daily screening, enrolment at the bedside,  
19  
20 organization of the schedule of tests with the attending medical team and daily data collection.  
21  
22 Follow-ups were performed locally with face-to-face questionnaire when patients were still in  
23  
24 hospital, or phone questionnaires, when discharged home or to another facility. Follow-ups were  
25  
26 made during working hours for most patients.  
27  
28  
29

### 30 **Start-up meeting**

31  
32 We organize a start-up meeting using virtual technology (video conference) prior to start  
33  
34 enrolment in the study. This start meeting was chaired by the study manager at the coordinating  
35  
36 center, involved the review of the protocol, the screening, enrolment and consent process, the  
37  
38 overall study procedure, and potential pitfalls to avoid during the process.  
39  
40  
41

### 42 **Central coordination and data monitoring**

43  
44 The study was coordinated centrally by a study manager assisted by a clinical research  
45  
46 coordinator. The study manager was responsible for supervising the implementation of the  
47  
48 study at each site and was the primary link for the local research team to answer questions and  
49  
50 queries during the conduction of the study. Communications through emails and phone calls to  
51  
52 participating sites were performed on regular basis to clarify potential issues on enrolment and  
53  
54 data collection, as well as to ascertain a close follow-up of sites. The data collection process  
55  
56 was monitored centrally at the coordinating center and answers queries sent to the participating  
57  
58  
59  
60

1  
2  
3 centers before case report forms were considered completed. A newsletter was disseminated  
4  
5 every other month to update center on the enrolment in the study, but also to motivate the team  
6  
7 and provide information on common queries and questions.  
8

### 9 10 **Sample size**

11  
12 With a sample size of 50 patients we predicted to estimate a compliance to the scheduled test  
13  
14 procedures of 90% with a margin of error of 10%.  
15  
16

### 17 18 **Statistical Analyses**

19  
20 Descriptive statistics were used to report the data. Data on compliance to the tests procedure,  
21  
22 enrolment rate, compliance to follow-up and overall study adherence are presented using  
23  
24 proportions. No comparative statistical testing was performed considering the feasibility nature  
25  
26 of this study.  
27  
28  
29  
30  
31  
32

## 33 34 **RESULTS**

### 35 36 37 **Patient enrolment**

38  
39 Over a 12-month period (May 2012 to May 2013) totalising 208 weeks of active enrolment (all  
40  
41 centers considered), participating centres screened 530 patients from which 116 were  
42  
43 potentially eligible and 50 were enrolled (43%). The two main reasons for non-enrolment were  
44  
45 the time-window for inclusion being after regular working hours and personnel oversight (Figure  
46  
47 2). We observed few refusals from surrogate decision makers and physicians, as well as non-  
48  
49 enrolment due to the absence of a surrogate decision maker. No patient, once included in the  
50  
51 study, was excluded. One center did not succeed to implement the study due to staffing issues  
52  
53 and did not contribute any patients to this feasibility trial. The majority of recruitment (32  
54  
55  
56  
57  
58  
59  
60

patients, 64%) took place during weekdays; three of the centers enrolled patients on weekends. Informed consent was mostly obtained (41 patients, 82%) between 9:00 am and 6:00 pm.

### Patient characteristics

The median age of participants was 45 years (Interquartile range (IQR), 29 – 60 years) and 80% were male (40 patients, 80%). The median GCS at enrolment was 6 (IQR: 3-7) and the Injury Severity Score (ISS) was 38 (IQR 25-50) (Table 1). In 88% of patients, traumatic brain injury occurred following motor vehicle collision (MVC) or fall.

**Table 1. Patients demographic**

Characteristics	Patients (n=50)
Age (median, IQR)	45 (29 – 60)
Male (n, %)	40 (80%)
GCS (median, IQR)	6 (3 - 7)
APACHE II score (mean $\pm$ SD)	20.2 $\pm$ 6.84
ISS score (median, IQR)	38 (25 - 30)
Absent pupillary reactivity (ICU day 1)	36 (72%)
Absent corneal reflex (ICU day 1)	7 (14%)
<b>Cause of trauma (n, %)</b>	
MVC-occupant	21 (42%)
MVC-motorcyclist	9 (18%)
MVC-pedestrian	2 (4%)
Fall	14 (28%)
Assault	2 (4%)
Other	2 (4%)



1  
2  
3 IQR: Interquartile range; GCS: Glasgow Coma Scale; MVC: Motor vehicle collision SD:  
4 Standard Deviation; APACHE: Acute Physiology and Chronic Health Evaluation; ISS: Injury  
5 Severity Score, ICU: Intensive care unit  
6  
7

### 8 9 **Compliance to the daily clinical data collection**

10  
11 Clinical data for episodes of hypotension, hypoxemia and increased intracranial pressure were  
12  
13 successfully collected. We had three missing time points for pupillary reaction (2 patients) and  
14  
15 one time point for the GCS (1 patient). Data for the corneal reflex was however missed at least  
16  
17 for one data point in 29 patients.  
18

### 19 20 **Compliance to the test procedures**

21  
22 The compliance to the protocol of test procedures ranged from 92% to 100%, depending on the  
23  
24 test performed. Compliance to tests was measured according to the survival status during the  
25  
26 time window in which the test was scheduled (Figure 3). We observed 94% compliance for  
27  
28 SSEP (3 missed tests), 96% for EEG (2 missed tests), and 92% for MRI (4 missed tests). Day 7  
29  
30 MRI was delayed for 20% (n=10) of the patients, most of them (n=6) due to the presence of  
31  
32 material incompatible with the performance of the MRI procedure. No CT-scans were missed on  
33  
34 day 1 and 3, while the compliance for day 7 CT-scans was 96% (2 missed scans). All but one  
35  
36 blood sample were collected (day 7); all collected blood samples were successfully shipped to  
37  
38 the coordinating centers. The main reason for not conducting a specific test was a change in  
39  
40 level of care (palliative care). The main explanation for performing tests outside of the time  
41  
42 window was patient instability (hemodynamic or increased intracranial pressure). We observed  
43  
44 no adverse events related to this study and tests performed.  
45  
46  
47  
48  
49  
50

### 51 52 **Follow-up of outcome measures**

53  
54 Two patients were lost to follow-up at 12 months, but none were at 6 months. Overall, 33  
55  
56 patients (66%) had an unfavourable outcome at 12 months (GOSe 1-4). Mortality was 38%  
57  
58  
59  
60

1  
2  
3 (19/50) and most deaths were associated with a decision to withdraw life-sustaining therapies  
4  
5 (18/19). No patient died during follow-up after hospital discharge.  
6  
7  
8  
9

## 10 **INTERPRETATION**

11  
12 In this multicenter prospective feasibility study, we achieved high compliance with the study  
13 procedures, an acceptable enrolment rate and had a low rate of loss to follow-up. All except one  
14 center achieved acceptable enrolment during the study period. The lessons learned during this  
15 multicenter feasibility prospective study have informed the design of the TBI-Prognosis  
16 multicenter prospective study (NCT02452541), which is currently ongoing.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 The high compliance rate to the test procedures observed in our study is a paramount result for  
28 the feasibility of the large-scale study. Several reasons may explain this high compliance. First,  
29 our protocol is straightforward and mainly relies on reminders for timely test procedures. Second,  
30 the uniformity of the tests and the flexibility of test timing allow these tests to be included  
31 seamlessly into the patient's care continuum. Third, adherence to the test schedule has also  
32 been facilitated by local research coordinators directly interacting with the clinical personnel in  
33 the intensive care unit and championing the project,[33] and by clinician guidance and  
34 enthusiasm towards the project.[34] Finally, we engaged the clinical personnel working in the  
35 intensive care unit by holding information sessions describing the project and by being available  
36 to answer their queries and concerns.[33, 35]  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 Pilot and feasibility studies are particularly useful in revealing study flaws and design  
53 weaknesses.[36-38] In this feasibility study, we also identified some potential challenges for the  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 enrolling patients admitted outside of regular working hours (evenings or week-ends). This  
4  
5 finding that a significant proportion of patients with traumatic brain injury are admitted over the  
6  
7 week-end was also observed in a previous cohort study of patients with mild to severe traumatic  
8  
9 brain injury in the UK.[39] Due to budgetary restrictions, but also to the available workforce, it  
10  
11 was not always possible to have 24-hour coverage for screening and enrolment in clinical  
12  
13 research. Using a deferred consent approach in all centers for the large-scale study is one of  
14  
15 the avenues considered to handle this potential issue. Another important finding is our follow-up  
16  
17 rates at 6 and 12 months that are comparable or better to the ones observed in previous large  
18  
19 scale multicenter trials in patient with severe traumatic brain injury.[40, 41] Despite having  
20  
21 missed 2 patients for the 12-month follow-up, we were able to follow all patients at 6 months, a  
22  
23 result showing the possibility of not missing any patients for the large scale study.  
24  
25  
26  
27  
28  
29  
30

31 Following this feasibility phase of the TBI-Prognosis study, study investigators engaged with  
32  
33 local investigators, intensive care unit nurses, and research coordinators, through both informal  
34  
35 discussions and survey, to understand their experience participating in the TBI-prognosis  
36  
37 feasibility study. Recruitment techniques and eligibility criteria were revised and refined to  
38  
39 improve clarity in the larger study. Deferred consent was highlighted as being especially helpful  
40  
41 given the time constraints and appears to be generally accepted by participants upon regaining  
42  
43 the ability to participate in the shared decision-making consent process.[42, 43] Indeed, the two  
44  
45 centers that implemented this method recruited a greater number of patients than the other sites  
46  
47 in accordance with the duration of the screening period. Strategies for approaching families in  
48  
49 time of stress were also discussed.[37] With much preparatory work completed, the TBI-  
50  
51 Prognosis team and the Canadian Critical Care Trials Group are now undertaking the large  
52  
53 multicenter prospective cohort study informed by the results of this pilot feasibility study.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In this multicenter prospective feasibility study, we successfully enrolled participants following  
4 an acceptable enrolment rate, reached our targeted sample size, achieved feasibility objectives  
5 pertaining to the compliance to the test procedures, compliance to follow-up, as well as the  
6 overall adherence the study protocol. Considering our enrolment rate, we considered that three  
7 years will be necessary to enrol 315 patients in 17 centers across Canada in the large-scale  
8 TBI-Prognosis study. We conclude that a prospective multicentre study in severe traumatic  
9 brain injury patients in Canada aiming at developing a prognostic model in the acute phase of  
10 care is feasible.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **ACKNOWLEDGMENTS**

29  
30 We would like to acknowledge Ramona-Florina Fratu for her help in the statistical analyses, as  
31 well as Catherine Ouellet for assembling the data. We are grateful to members of the Canadian  
32 Critical Care Trials Group (CCCTG) for their support and guidance, and for CCCTG Grants and  
33 Manuscript Committee and Paule Lessard Bonaventure for the critical review of this manuscript.  
34  
35 The authors also thank all the research coordinators and research professionals who were  
36 involved with this study for their help and dedication.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **CONTRIBUTIONS**

53  
54 AFT, FL, RZ, DAF, LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, JP, JLG, AL, KR, GP, DZ and  
55 LM were involved in conception and design. AFT, FL, RZ, DAF, CL, LAM, FB, AR, KB, DG, RG,  
56 DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were involved in the acquisition  
57  
58  
59  
60

1  
2 and interpretation of data. AFT, CL and MSh drafted the manuscript. AFT, FL, RZ, DAF, CL,  
3  
4 LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were  
5  
6 involved in revising the manuscript and approved the version published.  
7  
8  
9

## 10 11 **COMPETING INTERESTS**

12  
13  
14 The authors declared no competing interests.  
15  
16  
17

## 18 19 **FUNDING AND FINANCIAL DISCLOSURE**

20  
21 This study was funded by the Fonds de la Recherche du Québec - Santé (FRQS) (grant #5888)  
22  
23 and the Canadian Intensive Care Foundation (CICF). Dr Turgeon is the Canada Research Chair  
24  
25 in Critical Care Neurology and Trauma. Drs Moore, McIntyre, Turgeon and Zarychanski are or  
26  
27 were recipients of New Investigator Awards from the Canadian Institutes of Health Research  
28  
29 (CIHR) during the conduction of the study. Dr Turgeon and Lauzier are supported by the  
30  
31 Traumatology Research Consortium of the FRQS. Dr Lauzier is a recipient of a salary support  
32  
33 Award from the FRQS. The authors have no conflict of interest to declare.  
34  
35  
36  
37  
38  
39  
40

## 41 **DATA SHARING**

42  
43 There are no additional unpublished data available.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. National Scientific Advisory Committee. Identifying priorities for research and capacity development in injury as a multi-institute strategic initiative within the Canadian Institutes of Health Research. In: Listening for Direction on Injury: final report. Canada: Instituts canadiens de recherche en santé, 2004.
2. Medical aspects of the persistent vegetative state. The Multi-Society Task Force on PVS. *N Engl J Med* 1994;330:1499-508.
3. Lannoo E, Van Rietvelde F, Colardyn F, et al. Early predictors of mortality and morbidity after severe closed head injury. *J Neurotrauma* 2000;17:403-14.
4. Levati A, Farina ML, Vecchi G, et al. Prognosis of severe head injuries. *J Neurosurg* 1982;57:779-83.
5. Zygun DA, Laupland KB, Hader WJ, et al. Severe traumatic brain injury in a large Canadian health region. *Can J Neurol Sci* 2005;32:87-92.
6. Meerding WJ, Mulder S, van Beeck EF. Incidence and costs of injuries in The Netherlands. *Eur J Public Health* 2006;16:272-8.
7. Kramer AH, Zygun DA. Neurocritical care: why does it make a difference? *Curr Opin Crit Care* 2014;20:174-81.
8. Turgeon AF, Lauzier F, Simard JF, et al. Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study. *CMAJ* 2011;183:1581-8.
9. van Beinum A, Hornby L, Ramsay T, et al. Exploration of Withdrawal of Life-Sustaining Therapy in Canadian Intensive Care Units. *J Intensive Care Med* 2016;31:243-51.
10. Huynh TN, Walling AM, Le TX, et al. Factors associated with palliative withdrawal of mechanical ventilation and time to death after withdrawal. *J Palliat Med* 2013;16:1368-74.

- 1  
2  
3 11. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage  
4  
5 may lead to self-fulfilling prophecies. *Neurology* 2001;56:766-72.  
6
- 7  
8 12. Mayer SA, Kossoff SB. Withdrawal of life support in the neurological intensive care unit.  
9  
10 *Neurology* 1999;52:1602-9.  
11
- 12  
13 13. O'Callahan JG, Fink C, Pitts LH, et al. Withholding and withdrawing of life support from  
14  
15 patients with severe head injury. *Crit Care Med* 1995;23:1567-75.  
16
- 17  
18 14. Muehlschlegel, S., Shutter, L., Col, N. et al. *Neurocrit Care* (2015) 23: 127.  
19  
20 doi:10.1007/s12028-014-0097-2  
21
- 22  
23 15. Cote N, Turgeon AF, Lauzier F, et al. Factors associated with the withdrawal of life-  
24  
25 sustaining therapies in patients with severe traumatic brain injury: a multicenter cohort  
26  
27 study. *Neurocrit Care* 2013;18:154-60.  
28
- 29  
30 16. Brain Trauma Foundation, American Association of Neurological Surgeons, Joint section on  
31  
32 neurotrauma and critical care. *Management and prognosis of severe traumatic brain*  
33  
34 *injury*. New York, USA: Brain Trauma Foundation, 2000.  
35
- 36  
37 17. Lai YC, Chen FG, Goh MH, et al. Predictors of long-term outcome in severe head injury.  
38  
39 *Ann Acad Med Singapore* 1998;27:326-31.  
40
- 41  
42 18. Rovlias A, Kotsou S. Classification and regression tree for prediction of outcome after  
43  
44 severe head injury using simple clinical and laboratory variables. *J Neurotrauma*  
45  
46 2004;21:886-93.  
47
- 48  
49 19. Andrews PJ, Sleeman DH, Statham PF, et al. Predicting recovery in patients suffering from  
50  
51 traumatic brain injury by using admission variables and physiological data: a comparison  
52  
53 between decision tree analysis and logistic regression. *J Neurosurg* 2002;97:326-36.  
54
- 55  
56 20. Demetriades D, Kuncir E, Velmahos GC, et al. Outcome and prognostic factors in head  
57  
58 injuries with an admission Glasgow Coma Scale score of 3. *Arch Surg* 2004;139:1066-8.  
59  
60

- 1  
2  
3 21. Fearnside MR, Cook RJ, McDougall P, et al. The Westmead Head Injury Project outcome in  
4  
5 severe head injury. A comparative analysis of pre-hospital, clinical and CT variables. *Br J*  
6  
7 *Neurosurg* 1993;7:267-79.  
8
- 9  
10 22. Signorini DF, Andrews PJ, Jones PA, et al. Adding insult to injury: the prognostic value of  
11  
12 early secondary insults for survival after traumatic brain injury. *J Neurol Neurosurg*  
13  
14 *Psychiatry* 1999;66:26-31.  
15
- 16  
17 23. Walder AD, Yeoman PM, Turnbull A. The abbreviated injury scale as a predictor of outcome  
18  
19 of severe head injury. *Intensive care medicine* 1995;21:606-9.  
20
- 21  
22 24. Choi SC, Narayan RK, Anderson RL, et al. Enhanced specificity of prognosis in severe head  
23  
24 injury. *J Neurosurg* 1988;69:381-5.  
25
- 26  
27 25. Hsu MH, Li YC, Chiu WT, et al. Outcome prediction after moderate and severe head injury  
28  
29 using an artificial neural network. *Stud Health Technol Inform* 2005;116:241-5.  
30
- 31  
32 26. Hukkelhoven CW, Steyerberg EW, Habbema JD, et al. Predicting outcome after traumatic  
33  
34 brain injury: development and validation of a prognostic score based on admission  
35  
36 characteristics. *J Neurotrauma* 2005;22:1025-39.  
37
- 38  
39 27. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain  
40  
41 injury: results from the IMPACT study. *J Neurotrauma* 2007;24:329-37.  
42
- 43  
44 28. Perel P, Arango M, Clayton T, et al. Predicting outcome after traumatic brain injury: practical  
45  
46 prognostic models based on large cohort of international patients. *BMJ* 2008;336:425-9.  
47
- 48  
49 29. Turgeon AF, Lauzier F, Burns KE, et al. Determination of neurologic prognosis and clinical  
50  
51 decision making in adult patients with severe traumatic brain injury: a survey of Canadian  
52  
53 intensivists, neurosurgeons, and neurologists. *Crit Care Med* 2013;41:1086-93.  
54
- 55  
56 30. Turgeon AF, Lauzier F, Scales DC, et al. Practice variation in the management and  
57  
58 treatment of increased intracranial pressure in severe traumatic brain injury in Canada: a  
59  
60 Canadian multicentre retrospective cohort study [abstract]. *Crit Care Med* 2009;37:A435.



- 1  
2  
3 31. Jennett B, Bond MR. Assessment of outcome after severe brain damage. *Lancet*  
4  
5 1975;1:480-4.  
6
- 7  
8 32. Jennett B, Snoek J, Bond M, et al. Disability after severe head injury: observations on the  
9  
10 use of the Glasgow Outcome Scale. *J Neurol Neurosurg Psychiatry* 1981;44:285-93.  
11
- 12  
13 33. Tyson SF, Thomas N, Vail A, et al. Recruiting to inpatient-based rehabilitation trials: lessons  
14  
15 learned. *Trials* 2015;16:588.  
16
- 17  
18 34. Fletcher B, Gheorghe A, Moore D, et al. Improving the recruitment activity of clinicians in  
19  
20 randomised controlled trials: a systematic review. *BMJ open* 2012;2:e000496.  
21
- 22  
23 35. Dickson S, Logan J, Hagen S, et al. Reflecting on the methodological challenges of  
24  
25 recruiting to a United Kingdom-wide, multi-centre, randomised controlled trial in  
26  
27 gynaecology outpatient settings. *Trials* 2013;14:389.  
28
- 29  
30 36. Blanton S, Morris DM, Prettyman MG, et al. Lessons learned in participant recruitment and  
31  
32 retention: the EXCITE trial. *Phys Ther* 2006;86:1520-33.  
33
- 34  
35 37. Gardner G, Gardner A, MacLellan L, et al. Reconceptualising the objectives of a pilot study  
36  
37 for clinical research. *Int J Nurs Stud* 2003;40:719-24.  
38
- 39  
40 38. McIntyre LA, Fergusson D, Cook DJ, et al. Fluid resuscitation in the management of early  
41  
42 septic shock (FINESS): a randomized controlled feasibility trial. *Can J Anaesth*  
43  
44 2008;55:819-26.  
45
- 46  
47 39. Harrison DA, Prabhu G, Grieve R, Harvey SE, Sadique MZ, Gomes M, et al . Risk  
48  
49 Adjustment In Neurocritical care (RAIN) – prospective validation of risk prediction models  
50  
51 for adult patients with acute traumatic brain injury to use to evaluate the optimum location  
52  
53 and comparative costs of neurocritical care: a cohort study. *Health Technol*  
54  
55 *Assess* 2013;17 (23).  
56
- 57  
58 40. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after  
59  
60 Traumatic Brain Injury. *N Engl J Med* 2015;373:2403-12.

- 1  
2  
3 41. Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for  
4 acute traumatic brain injury. *N Engl J Med* 2014;371:2457-66.  
5  
6  
7 42. Potter JE, McKinley S, Delaney A. Research participants' opinions of delayed consent for a  
8 randomised controlled trial of glucose control in intensive care. *Intensive care medicine*  
9 2013;39:472-80.  
10  
11  
12 43. Gamble C, Nadel S, Snape D, et al. What parents of children who have received emergency  
13 care think about deferring consent in randomised trials of emergency treatments: postal  
14 survey. *PloS one* 2012;7:e35982.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure 1. TBI-Prognosis test schedule.**

4 The arrows indicate the prescribed time frame to perform tests or take blood samples. The  
5 study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the  
6 scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7.  
7 The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before  
8 or after the seventh day.  
9

10  
11 CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit;  
12 MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials  
13

14  
15 **Figure 2. Reasons for non-enrolment**

16  
17  
18 SDM: Shared Decision Making  
19

20  
21  
22 **Figure 3. Compliance to the scheduled test procedures**

23  
24  
25 CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit;  
26 MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	ICU Day 1	ICU Day 2	ICU Day 3	ICU Day 4	ICU Day 5	ICU Day 6	ICU Day 7	ICU Day 8	ICU Day 9		
CT-scan (+/- 24 hrs)	←→		←→			←→					
Blood samples (biomarkers)	←→		←→							←→	
EEG, SSEP, MRI (+/- 48 hrs)					←→						

Figure 1. TBI-Prognosis test schedule. ++ The arrows indicate the prescribed time frame to perform tests or take blood samples. The study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7. The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before or after the seventh day. CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

173x77mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Reasons for non-enrolment.† SDM: Shared Decision Making

173x129mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. Compliance to the scheduled test procedures. CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

173x107mm (300 x 300 DPI)

view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,8, Figure 1
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	Part of pilot goal
		(d) If applicable, explain how loss to follow-up was addressed	Part of pilot goal
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9, Figure 2
		(c) Consider use of a flow diagram	No
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	10, 11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	9, 10, 11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9, 10, 11
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11, 12
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	5, 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12, 13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Prognostication in critically ill patients with severe traumatic brain injury: The TBI-Prognosis multicenter feasibility study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013779.R2
Article Type:	Research
Date Submitted by the Author:	08-Feb-2017
Complete List of Authors:	<p>Turgeon, Alexis; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Lauzier, François; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Anesthesiology and Critical Care Medicine</p> <p>Zarychanski, Ryan; University of Manitoba, Department of Internal Medicine, Sections of Critical Care Medicine and of Haematology/Medical Oncology</p> <p>Fergusson, Dean; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Leger, Caroline; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>McIntyre, Lauralyn; Ottawa Hospital Research Institute, Department of Critical Care Medicine; Ottawa Hospital Research Institute, Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit</p> <p>Bernard, Francis ; Université de Montréal, Department of Medicine</p> <p>Rigamonti, Andrea; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Burns, Karen E. A.; University of Toronto, Interdepartmental Division of Critical Care Medicine, Saint Michael's Hospital</p> <p>Griesdale, Donald; University of British Columbia, Department of Anesthesiology, Pharmacology &amp; Therapeutics</p> <p>Green, Robert; Dalhousie University, Department of Emergency Medicine</p> <p>Scales, Damon; University of Toronto, Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital</p> <p>Meade, Maureen; McMaster University, Department of Critical Care Medicine</p> <p>Savard, Martin; Université Laval, Department of Psychiatry and Neurosciences</p> <p>Shemilt, Michele; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit (Trauma - Emergency - Critical Care Medicine)</p> <p>Paquet, Jérôme; Université Laval, Department of Surgery</p> <p>Gariépy, Jean-Luc; Université Laval, Department of Radiology and Nuclear Medicine</p> <p>Lavoie, André; Centre de Recherche du CHU de Québec - Université Laval,</p>

	Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine) Reddy, Kesh; McMaster University, Department of Critical Care Medicine Jichici, Draga; McMaster University, Department of Critical Care Medicine Pagliarello, Giuseppe; Ottawa Hospital Research Institute, Department of Critical Care Medicine Zygun, David; University of Alberta, Department of Critical Care Medicine Moore, Lynne; Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practives Research Unit (Trauma - Emergency - Critical Care Medicine); Université Laval, Department of Preventive and Social Medicine
<b>Primary Subject Heading</b> :	Intensive care
<b>Secondary Subject Heading</b> :	Epidemiology
<b>Keywords</b> :	Traumatic brain injury, Pilot study, Prognosis, Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Outcome

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Prognostication in critically ill patients with severe traumatic brain injury:**  
5  
6 **The TBI-Prognosis multicenter feasibility study**  
7  
8  
9

10  
11  
12  
13 Alexis F. Turgeon<sup>1,2</sup> MD MSc FRCPC, François Lauzier<sup>1,2</sup> MD MSc FRCPC, Ryan Zarychanski<sup>3</sup>  
14 MD MSc FRCPC, Dean A. Fergusson<sup>4</sup> PhD, Caroline Léger<sup>1</sup> PhD, Lauralyn A McIntyre<sup>4,5</sup> MD  
15 MSc FRCPC, Francis Bernard<sup>6</sup> MD FRCPC, Andrea Rigamonti<sup>7</sup> MD FRCPC, Karen Burns<sup>7</sup> MD  
16 MSc, Don Griesdale<sup>8</sup> MD MSc FRCPC, Robert Green<sup>9</sup> MD, Damon C Scales<sup>10</sup> MD PhD  
17 FRCPC, Maureen O. Meade<sup>11</sup> MD MSc FRCPC, Martin Savard<sup>12</sup> MD FRCPC, Michèle Shemilt<sup>1</sup>  
18 MSc, Jérôme Paquet<sup>13</sup> MD FRCPC, Jean-Luc Gariépy<sup>13</sup> MD FRCPC, André Lavoie<sup>1</sup> PhD, Kesh  
19 Reddy<sup>11</sup> MD FRCSC, Draga Jichici<sup>11</sup> MD FRCPC, Giuseppe Pagliarello<sup>5</sup> MD FRCPC, David  
20 Zygun<sup>14</sup> MD MSc FRCPC, Lynne Moore<sup>1,15</sup> PhD, for the TBI-Prognosis study team and the  
21 Canadian Critical Care Trials Group.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 <sup>1</sup> Centre de Recherche du CHU de Québec - Université Laval, Population Health and Optimal  
39 Health Practices Research Unit (Trauma – Emergency – Critical Care Medicine), Québec City,  
40 Québec, Canada.  
41  
42  
43

44 <sup>2</sup> Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine,  
45 Université Laval, Québec City, Québec, Canada.  
46  
47  
48

49 <sup>3</sup> Department of Internal Medicine, Section of Critical Care and of Haematology and Medical  
50 Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.  
51  
52  
53

54 <sup>4</sup> Center for Transfusion and Critical Care Research, Clinical Epidemiology Unit, Ottawa Health  
55 Research Institute, University of Ottawa, Ottawa, Ontario, Canada.  
56  
57  
58  
59  
60

1  
2  
3 <sup>5</sup> Department of Critical Care Medicine, Ottawa Hospital, University of Ottawa, Ottawa, Ontario,  
4  
5 Canada.

6  
7 <sup>6</sup> Department of Medicine, Université de Montréal, Montréal, Québec, Canada.

8  
9  
10 <sup>7</sup> Interdepartmental Division of Critical Care Medicine, St-Michael's Hospital, University of  
11  
12 Toronto, Toronto, Ontario, Canada.

13  
14 <sup>8</sup> Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia  
15  
16 Vancouver, BC, Canada.

17  
18  
19 <sup>9</sup> Department of Emergency Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

20  
21  
22 <sup>10</sup> Interdepartmental Division of Critical Care Medicine, Sunnybrook Hospital, University of  
23  
24 Toronto, Toronto, Ontario, Canada.

25  
26  
27 <sup>11</sup> Department of Critical Care Medicine, McMaster University, Hamilton, Ontario, Canada.

28  
29 <sup>12</sup> Department of Psychiatry and Neurosciences, Université Laval, Québec, Québec, Canada.

30  
31 <sup>13</sup> Department Radiology and Nuclear Medicine, Université Laval, Québec, Québec, Canada.

32  
33  
34 <sup>14</sup> Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada.

35  
36  
37 <sup>15</sup> Department of Preventive and Social Medicine, Université Laval, Québec, Québec, Canada.

38  
39 **Corresponding author:**

40  
41 Alexis F. Turgeon MD MSc FRCPC

42  
43 CHU de Québec - Université Laval Research Center

44  
45 Population Health and Optimal Health Practices Research Unit

46  
47 (Trauma - Emergency - Critical Care Medicine)

48  
49 1401, 18e rue, local H-037, Québec (Québec), G1J 1Z4

50  
51 Phone: 418-649-0252 #66064

52  
53 Email: alexis.turgeon@fmed.ulaval.ca

54  
55  
56  
57  
58 **Word Count: 2824**

1  
2  
3  
4  
5 **Keywords:** traumatic brain injury, prognosis, multicenter study, feasibility, feasibility study  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**ABSTRACT** (292 words)

**Objective:** Severe traumatic brain injury is a significant cause of morbidity and mortality in young adults. Assessing long-term neurological outcome after such injury is difficult and often characterized by uncertainty. The objective of this feasibility study was to establish the feasibility of conducting a large, multicenter prospective study to develop a prognostic model of long-term neurological outcome in critically ill patients with severe traumatic brain injury.

**Design:** Prospective cohort study.

**Setting:** Nine Canadian intensive care units enrolled patients suffering from acute severe traumatic brain injury. Clinical, biological, radiological and electrophysiological data were systematically collected during the first week in the intensive care unit. Mortality and functional outcome (Glasgow Outcome Scale extended) were assessed upon hospital discharge, and then 3, 6 and 12 months following injury.

**Outcomes:** The compliance to protocolized test procedures was the primary outcome. Secondary outcomes were enrolment rate and compliance to follow-up.

**Results:** We successfully enrolled 50 patients over a 12-month period. Most patients were male (80%), with a median age of 45 years (IQR 29.0 – 60.0), a median Injury Severity Score (ISS) of 38 (IQR 25-50), and a GCS of 6 (IQR 3-7). Mortality was 38% (19/50) and most deaths occurred following a decision to withdraw life-sustaining therapies (18/19). The main reasons for non-enrollment were the time window for inclusion being after regular working hours (35%, n=23) and oversight (24%, n=16). Compliance with protocolized test procedures ranged from 92% to 100% and enrolment rate was 43%. No patients were lost to follow-up at 6 months and 2 were at 12 months.

**Conclusion:** In this multicenter prospective feasibility study, we achieved feasibility objectives pertaining to compliance to test, enrolment and follow-up. We conclude that the TBI-Prognosis prospective multicentre study in severe traumatic brain injury patients in Canada is feasible.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Our study involved nine centers in five different provinces in Canada and showed the feasibility of enrolling critically ill patients with severe traumatic brain injury and assess 12-months outcome measures.
- Our study sample size allowed testing a protocol of test procedures and identifying potential pitfalls to consider for a large-scale prognostic study.
- Some eligible patients were missed due to an admission to the intensive care unit outside of working hours or were oversight by the research personnel.

## INTRODUCTION

Severe traumatic brain injuries are catastrophic injuries primarily afflicting young individuals.[1] Mortality ranges from 30 to 50%, while 30% of survivors suffer from severe neurological sequelae.[2-5] Given the majority of victims are young with previous excellent quality of life, substantive human, social and financial repercussions are experienced by survivors.[6]

With regard to victims of severe traumatic brain injury, physicians and families often face important treatment decisions. They must decide to either undertake aggressive care in the hope of the patient will survive with an acceptable quality of life[7-10] or to withdraw life-sustaining therapy considering an unfavourable and undesirable prognosis. Serious concerns have been expressed regarding early decisions made to withdraw life-sustaining therapies in absence of evidence-based prognostic information.[11-14] Recently, we observed significant variations in mortality and in the incidence of withdrawal of life-sustaining therapies following severe traumatic brain injury in Canada.[8, 15] Current prognostic models are of limited clinical utility as they are based on data obtained from small[16-18], single centre[3, 17-23] retrospective studies[17, 22, 24-26] that did not consider secondary brain injury.[3, 17-21, 23, 24, 27-28] Consequently, it is not surprising to observe a wide variation in prognostic evaluation when surveying intensivists, neurosurgeons and neurologists caring for severe traumatic brain injury in Canada.[29] The development of appropriate prognosis tools and models is necessary to help guide the decision making process with families.

The objective of the TBI-Prognosis Feasibility Study was to assess the feasibility of a conducting a large-scale, multicentre study to develop a prognostic model to inform long-term prognosis in patients with severe traumatic brain injury.



## METHODS

### Study design

We conducted a multicentre prospective feasibility study in 9 level I trauma centres across Canada. Research Ethics Board approval was obtained from each participating center. Informed consent was obtained from surrogate decision makers prior to enrolment in most centers; deferred consent was permitted by Research Ethics Boards at two centers. This study was conducted in the Canadian health care system in which trauma, neurosurgery and critical care are part of a public system with universal health care coverage for all citizens. In Canada, major trauma care is delivered through 10 integrated provincial trauma systems. In Canada, neurocritical care is mainly delivered in combined neuro/general intensive care units.

### Eligibility criteria

We included critically ill adults ( $\geq 18$  years of age) with severe traumatic brain injury (Glasgow coma scale (GCS)  $\leq 8$  following resuscitation) due to blunt-force trauma on day 1 of intensive care unit admission. We excluded patients anticipated to be on mechanical ventilation for less than 48 hours, patients with solid malignancy associated with a life expectancy less than 12 months, liver cirrhosis Child C, chronic heart failure (NYHA class IV), end-stage chronic respiratory disease ( $O_2$  dependent), end-stage renal disease (chronic dialysis), previous neurologic disorder with abnormal findings on radiological imaging (CT-scan, magnetic resonance imaging (MRI)) or electrophysiological tests (electroencephalogram (EEG), somatosensory evoked potentials (SSEP)) or patients who were declared brain-dead when assessed for eligibility. Patients with no fixed address were also excluded due to difficulties in conducting follow-up.

### Data collection

1  
2  
3 Participants underwent a protocolized schedule of clinical, biological, radiological, and  
4  
5 electrophysiological prognostic tests or examinations. Tests and examinations used in our study  
6  
7 were commonly utilized in the care of patients with severe traumatic brain injury for diagnostic or  
8  
9 prognostic purposes except for blood samples. Data were collected daily from intensive care  
10  
11 unit admission until the 7<sup>th</sup> day following the injury, death or until hospital discharge, whichever  
12  
13 came first. These included pupillary reactivity, corneal reflex, GCS, episodes of increased  
14  
15 intracranial hypertension (>25 mmHg), hypoxemia (arterial oxygen saturation of <90%) and  
16  
17 hypotension (systolic blood pressure <90 mm Hg). Data was prospectively collected at the  
18  
19 bedside using specific case report forms. We also collected serum glucose (highest and lowest  
20  
21 value), complete blood count, INR, prothrombin time, sodium, creatinine, arterial blood gases,  
22  
23 also on a daily basis if the data was available as per clinical decision by the medical team. A  
24  
25 schedule of prognostic biological, radiological and electrophysiological tests/examinations was  
26  
27 implemented (Figure 1). On intensive care unit day 1, 3 and 7, CT-scans were performed and  
28  
29 blood samples were collected to measure serum biomarkers. These timelines were informed by  
30  
31 a multicenter retrospective study and a health care survey of Canadian clinicians.[8, 29, 30] On  
32  
33 intensive care unit day 7, MRI, SSEP and EEG examinations were performed. We permitted a  
34  
35 time window of 24 hours (for CT-scan) and 48 hours (for MRI, SSEP and EEG) to reflect clinical  
36  
37 practice and enhance feasibility over weekends.  
38  
39  
40  
41  
42  
43  
44

### 45 **Outcome measures**

46  
47 Our overarching objective of the research program is to develop a model to predict short  
48  
49 (discharge), mid (3 months) and long-term neurological prognosis (6 and 12 months) in patients  
50  
51 admitted to intensive care unit with severe traumatic brain injury. The functional outcome was  
52  
53 evaluated using the Glasgow Outcome Scale extended (GOSe) (face to face (hospitalized  
54  
55 patients) or phone interviews (discharged patients)).[31, 32] Our feasibility study was designed  
56  
57 to establish the feasibility of a large scale study adequately powered to develop prognostic  
58  
59  
60

1  
2  
3 models to help inform clinical decision-making. Our primary outcome was the compliance rate to  
4  
5 the protocolized test procedures (tests performed or not performed). We considered a 90%  
6  
7 compliance rate to be acceptable. Secondary outcomes were enrolment rate and compliance to  
8  
9 follow-up. We also evaluated the percentage of potentially eligible patients that were excluded,  
10  
11 the reasons for exclusion and adverse events related to the protocol.  
12  
13

### 14 **Research team at participating centers**

15  
16 At each participating center, a research coordinator and/or research nurse, was involved in the  
17  
18 implementation of the study in the intensive care unit, daily screening, enrolment at the bedside,  
19  
20 organization of the schedule of tests with the attending medical team and daily data collection.  
21  
22 Follow-ups were performed locally with face-to-face questionnaire when patients were still in  
23  
24 hospital, or phone questionnaires, when discharged home or to another facility. Follow-ups were  
25  
26 made during working hours for most patients.  
27  
28  
29

### 30 **Start-up meeting**

31  
32 We organize a start-up meeting using virtual technology (video conference) prior to start  
33  
34 enrolment in the study. This start meeting was chaired by the study manager at the coordinating  
35  
36 center, involved the review of the protocol, the screening, enrolment and consent process, the  
37  
38 overall study procedure, and potential pitfalls to avoid during the process.  
39  
40  
41

### 42 **Central coordination and data monitoring**

43  
44 The study was coordinated centrally by a study manager assisted by a clinical research  
45  
46 coordinator. The study manager was responsible for supervising the implementation of the  
47  
48 study at each site and was the primary link for the local research team to answer questions and  
49  
50 queries during the conduction of the study. Communications through emails and phone calls to  
51  
52 participating sites were performed on regular basis to clarify potential issues on enrolment and  
53  
54 data collection, as well as to ascertain a close follow-up of sites. The data collection process  
55  
56 was monitored centrally at the coordinating center and answers queries sent to the participating  
57  
58  
59  
60

1  
2  
3 centers before case report forms were considered completed. A newsletter was disseminated  
4  
5 every other month to update center on the enrolment in the study, but also to motivate the team  
6  
7 and provide information on common queries and questions.  
8

### 9 10 **Sample size**

11  
12 With a sample size of 50 patients we predicted to estimate a compliance to the scheduled test  
13  
14 procedures of 90% with a margin of error of 10%.  
15  
16

### 17 18 **Statistical Analyses**

19  
20 Descriptive statistics were used to report the data. Data on compliance to the tests procedure,  
21  
22 enrolment rate, compliance to follow-up and overall study adherence are presented using  
23  
24 proportions. No comparative statistical testing was performed considering the feasibility nature  
25  
26 of this study.  
27  
28  
29  
30  
31  
32

## 33 34 **RESULTS**

### 35 36 37 **Patient enrolment**

38  
39 Over a 12-month period (May 2012 to May 2013) totalising 208 weeks of active enrolment (all  
40  
41 centers considered), participating centres screened 530 patients from which 116 were  
42  
43 potentially eligible and 50 were enrolled (43%). The two main reasons for non-enrolment were  
44  
45 the time-window for inclusion being after regular working hours and personnel oversight (Figure  
46  
47 2). We observed few refusals from surrogate decision makers and physicians, as well as non-  
48  
49 enrolment due to the absence of a surrogate decision maker. No patient, once included in the  
50  
51 study, was excluded. One center did not succeed to implement the study due to staffing issues  
52  
53 and did not contribute any patients to this feasibility trial. The majority of recruitment (32  
54  
55  
56  
57  
58  
59  
60

patients, 64%) took place during weekdays; three of the centers enrolled patients on weekends. Informed consent was mostly obtained (41 patients, 82%) between 9:00 am and 6:00 pm.

### Patient characteristics

The median age of participants was 45 years (Interquartile range (IQR), 29 – 60 years) and 80% were male (40 patients, 80%). The median GCS at enrolment was 6 (IQR: 3-7) and the Injury Severity Score (ISS) was 38 (IQR 25-50) (Table 1). In 88% of patients, traumatic brain injury occurred following motor vehicle collision (MVC) or fall.

**Table 1. Patients demographic**

Characteristics	Patients (n=50)
Age (median, IQR)	45 (29 – 60)
Male (n, %)	40 (80%)
GCS (median, IQR)	6 (3 - 7)
APACHE II score (mean $\pm$ SD)	20.2 $\pm$ 6.84
ISS score (median, IQR)	38 (25 - 30)
Absent pupillary reactivity (ICU day 1)	36 (72%)
Absent corneal reflex (ICU day 1)	7 (14%)
<b>Cause of trauma (n, %)</b>	
MVC-occupant	21 (42%)
MVC-motorcyclist	9 (18%)
MVC-pedestrian	2 (4%)
Fall	14 (28%)
Assault	2 (4%)
Other	2 (4%)

1  
2  
3 IQR: Interquartile range; GCS: Glasgow Coma Scale; MVC: Motor vehicle collision SD:  
4 Standard Deviation; APACHE: Acute Physiology and Chronic Health Evaluation; ISS: Injury  
5 Severity Score, ICU: Intensive care unit  
6  
7

### 8 9 **Compliance to the daily clinical data collection**

10  
11 Clinical data for episodes of hypotension, hypoxemia and increased intracranial pressure were  
12  
13 successfully collected. We had three missing time points for pupillary reaction (2 patients) and  
14  
15 one time point for the GCS (1 patient). Data for the corneal reflex was however missed at least  
16  
17 for one data point in 29 patients.  
18

### 19 20 **Compliance to the test procedures**

21  
22 The compliance to the protocol of test procedures ranged from 92% to 100%, depending on the  
23  
24 test performed. Compliance to tests was measured according to the survival status during the  
25  
26 time window in which the test was scheduled (Figure 3). We observed 94% compliance for  
27  
28 SSEP (3 missed tests), 96% for EEG (2 missed tests), and 92% for MRI (4 missed tests). Day 7  
29  
30 MRI was delayed for 20% (n=10) of the patients, most of them (n=6) due to the presence of  
31  
32 material incompatible with the performance of the MRI procedure. No CT-scans were missed on  
33  
34 day 1 and 3, while the compliance for day 7 CT-scans was 96% (2 missed scans). All but one  
35  
36 blood sample were collected (day 7); all collected blood samples were successfully shipped to  
37  
38 the coordinating centers. The main reason for not conducting a specific test was a change in  
39  
40 level of care (palliative care). The main explanation for performing tests outside of the time  
41  
42 window was patient instability (hemodynamic or increased intracranial pressure). We observed  
43  
44 no adverse events related to this study and tests performed.  
45  
46  
47  
48  
49  
50

### 51 52 **Follow-up of outcome measures**

53  
54 Two patients were lost to follow-up at 12 months, but none were at 6 months. Overall, 33  
55  
56 patients (66%) had an unfavourable outcome at 12 months (GOSe 1-4). Mortality was 38%  
57  
58  
59  
60

1  
2  
3 (19/50) and most deaths were associated with a decision to withdraw life-sustaining therapies  
4  
5 (18/19). No patient died during follow-up after hospital discharge.  
6  
7  
8  
9

## 10 **INTERPRETATION**

11  
12 In this multicenter prospective feasibility study, we achieved high compliance with the study  
13 procedures, an acceptable enrolment rate and had a low rate of loss to follow-up. All except one  
14 center achieved acceptable enrolment during the study period. The lessons learned during this  
15 multicenter feasibility prospective study have informed the design of the TBI-Prognosis  
16 multicenter prospective study (NCT02452541), which is currently ongoing.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27 The high compliance rate to the test procedures observed in our study is a paramount result for  
28 the feasibility of the large-scale study. Several reasons may explain this high compliance. First,  
29 our protocol is straightforward and mainly relies on reminders for timely test procedures. Second,  
30 the uniformity of the tests and the flexibility of test timing allow these tests to be included  
31 seamlessly into the patient's care continuum. Third, adherence to the test schedule has also  
32 been facilitated by local research coordinators directly interacting with the clinical personnel in  
33 the intensive care unit and championing the project,[33] and by clinician guidance and  
34 enthusiasm towards the project.[34] Finally, we engaged the clinical personnel working in the  
35 intensive care unit by holding information sessions describing the project and by being available  
36 to answer their queries and concerns.[33, 35]  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 Pilot and feasibility studies are particularly useful in revealing study flaws and design  
54 weaknesses.[36-38] In this feasibility study, we also identified some potential challenges for the  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2 enrolling patients admitted outside of regular working hours (evenings or week-ends). This  
3 finding that a significant proportion of patients with traumatic brain injury are admitted over the  
4 week-end was also observed in a previous cohort study of patients with mild to severe traumatic  
5 brain injury in the UK.[39] Due to budgetary restrictions, but also to the available workforce, it  
6 was not always possible to have 24-hour coverage for screening and enrolment in clinical  
7 research. Using a deferred consent approach in all centers for the large-scale study is one of  
8 the avenues considered to handle this potential issue. Another important finding is our follow-up  
9 rates at 6 and 12 months that are comparable or better to the ones observed in previous large  
10 scale multicenter trials in patient with severe traumatic brain injury.[40, 41] Despite having  
11 missed 2 patients for the 12-month follow-up, we were able to follow all patients at 6 months, a  
12 result showing the possibility of not missing any patients for the large scale study.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Following this feasibility phase of the TBI-Prognosis study, study investigators engaged with  
32 local investigators, intensive care unit nurses, and research coordinators, through both informal  
33 discussions and survey, to understand their experience participating in the TBI-prognosis  
34 feasibility study. Recruitment techniques and eligibility criteria were revised and refined to  
35 improve clarity in the larger study. Deferred consent was highlighted as being especially helpful  
36 given the time constraints and appears to be generally accepted by participants upon regaining  
37 the ability to participate in the shared decision-making consent process.[42, 43] Indeed, the two  
38 centers that implemented this method recruited a greater number of patients than the other sites  
39 in accordance with the duration of the screening period. Strategies for approaching families in  
40 time of stress were also discussed.[37] With much preparatory work completed, the TBI-  
41 Prognosis team and the Canadian Critical Care Trials Group are now undertaking the large  
42 multicenter prospective cohort study informed by the results of this pilot feasibility study.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 In this multicenter prospective feasibility study, we successfully enrolled participants following  
4 an acceptable enrolment rate, reached our targeted sample size, achieved feasibility objectives  
5 pertaining to the compliance to the test procedures, compliance to follow-up, as well as the  
6 overall adherence the study protocol. Considering our enrolment rate, we considered that three  
7 years will be necessary to enrol 315 patients in 17 centers across Canada in the large-scale  
8 TBI-Prognosis study. We conclude that a prospective multicentre study in severe traumatic  
9 brain injury patients in Canada aiming at developing a prognostic model in the acute phase of  
10 care is feasible.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **ACKNOWLEDGMENTS**

29  
30 We would like to acknowledge Ramona-Florina Fratu for her help in the statistical analyses, as  
31 well as Catherine Ouellet for assembling the data. We are grateful to members of the Canadian  
32 Critical Care Trials Group (CCCTG) for their support and guidance, and for CCCTG Grants and  
33 Manuscript Committee and Paule Lessard Bonaventure for the critical review of this manuscript.  
34  
35 The authors also thank all the research coordinators and research professionals who were  
36 involved with this study for their help and dedication.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **CONTRIBUTIONS**

53  
54 AFT, FL, RZ, DAF, LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, JP, JLG, AL, KR, GP, DZ and  
55 LM were involved in conception and design. AFT, FL, RZ, DAF, CL, LAM, FB, AR, KB, DG, RG,  
56 DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were involved in the acquisition  
57  
58  
59  
60

1  
2 and interpretation of data. AFT, CL and MSh drafted the manuscript. AFT, FL, RZ, DAF, CL,  
3  
4 LAM, FB, AR, KB, DG, RG, DCS, MOM, MS, MSh, JP, JLG, AL, KR, DJ, GP, DZ and LM were  
5  
6 involved in revising the manuscript and approved the version published.  
7  
8  
9

## 10 11 **COMPETING INTERESTS**

12  
13  
14 The authors declared no competing interests.  
15  
16  
17

## 18 19 **FUNDING AND FINANCIAL DISCLOSURE**

20  
21 This study was funded by the Fonds de la Recherche du Québec - Santé (FRQS) (grant #5888)  
22  
23 and the Canadian Intensive Care Foundation (CICF). Dr Turgeon is the Canada Research Chair  
24  
25 in Critical Care Neurology and Trauma. Drs Moore, McIntyre, Turgeon and Zarychanski are or  
26  
27 were recipients of New Investigator Awards from the Canadian Institutes of Health Research  
28  
29 (CIHR) during the conduction of the study. Dr Turgeon and Lauzier are supported by the  
30  
31 Traumatology Research Consortium of the FRQS. Dr Lauzier is a recipient of a salary support  
32  
33 Award from the FRQS. The authors have no conflict of interest to declare.  
34  
35  
36  
37  
38  
39  
40

## 41 **DATA SHARING**

42  
43 There are no additional unpublished data available.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. National Scientific Advisory Committee. Identifying priorities for research and capacity development in injury as a multi-institute strategic initiative within the Canadian Institutes of Health Research. In: Listening for Direction on Injury: final report. Canada: Instituts canadiens de recherche en santé, 2004.
2. Medical aspects of the persistent vegetative state. The Multi-Society Task Force on PVS. *N Engl J Med* 1994;330:1499-508.
3. Lannoo E, Van Rietvelde F, Colardyn F, et al. Early predictors of mortality and morbidity after severe closed head injury. *J Neurotrauma* 2000;17:403-14.
4. Levati A, Farina ML, Vecchi G, et al. Prognosis of severe head injuries. *J Neurosurg* 1982;57:779-83.
5. Zygun DA, Laupland KB, Hader WJ, et al. Severe traumatic brain injury in a large Canadian health region. *Can J Neurol Sci* 2005;32:87-92.
6. Meerding WJ, Mulder S, van Beeck EF. Incidence and costs of injuries in The Netherlands. *Eur J Public Health* 2006;16:272-8.
7. Kramer AH, Zygun DA. Neurocritical care: why does it make a difference? *Curr Opin Crit Care* 2014;20:174-81.
8. Turgeon AF, Lauzier F, Simard JF, et al. Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study. *CMAJ* 2011;183:1581-8.
9. van Beinum A, Hornby L, Ramsay T, et al. Exploration of Withdrawal of Life-Sustaining Therapy in Canadian Intensive Care Units. *J Intensive Care Med* 2016;31:243-51.
10. Huynh TN, Walling AM, Le TX, et al. Factors associated with palliative withdrawal of mechanical ventilation and time to death after withdrawal. *J Palliat Med* 2013;16:1368-74.

- 1  
2  
3 11. Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage  
4  
5 may lead to self-fulfilling prophecies. *Neurology* 2001;56:766-72.  
6
- 7  
8 12. Mayer SA, Kossoff SB. Withdrawal of life support in the neurological intensive care unit.  
9  
10 *Neurology* 1999;52:1602-9.
- 11  
12 13. O'Callahan JG, Fink C, Pitts LH, et al. Withholding and withdrawing of life support from  
13  
14 patients with severe head injury. *Crit Care Med* 1995;23:1567-75.  
15
- 16  
17 14. Muehlschlegel, S., Shutter, L., Col, N. et al. *Neurocrit Care* (2015) 23: 127-130  
18
- 19  
20 15. Cote N, Turgeon AF, Lauzier F, et al. Factors associated with the withdrawal of life-  
21  
22 sustaining therapies in patients with severe traumatic brain injury: a multicenter cohort  
23  
24 study. *Neurocrit Care* 2013;18:154-60.  
25
- 26  
27 16. Brain Trauma Foundation, American Association of Neurological Surgeons, Joint section on  
28  
29 neurotrauma and critical care. *Management and prognosis of severe traumatic brain*  
30  
31 *injury*. New York, USA: Brain Trauma Foundation, 2000.  
32
- 33  
34 17. Lai YC, Chen FG, Goh MH, et al. Predictors of long-term outcome in severe head injury.  
35  
36 *Ann Acad Med Singapore* 1998;27:326-31.  
37
- 38  
39 18. Rovlias A, Kotsou S. Classification and regression tree for prediction of outcome after  
40  
41 severe head injury using simple clinical and laboratory variables. *J Neurotrauma*  
42  
43 2004;21:886-93.  
44
- 45  
46 19. Andrews PJ, Sleeman DH, Statham PF, et al. Predicting recovery in patients suffering from  
47  
48 traumatic brain injury by using admission variables and physiological data: a comparison  
49  
50 between decision tree analysis and logistic regression. *J Neurosurg* 2002;97:326-36.  
51
- 52  
53 20. Demetriades D, Kuncir E, Velmahos GC, et al. Outcome and prognostic factors in head  
54  
55 injuries with an admission Glasgow Coma Scale score of 3. *Arch Surg* 2004;139:1066-8.  
56  
57  
58  
59  
60

21. Fearnside MR, Cook RJ, McDougall P, et al. The Westmead Head Injury Project outcome in severe head injury. A comparative analysis of pre-hospital, clinical and CT variables. *Br J Neurosurg* 1993;7:267-79.
22. Signorini DF, Andrews PJ, Jones PA, et al. Adding insult to injury: the prognostic value of early secondary insults for survival after traumatic brain injury. *J Neurol Neurosurg Psychiatry* 1999;66:26-31.
23. Walder AD, Yeoman PM, Turnbull A. The abbreviated injury scale as a predictor of outcome of severe head injury. *Intensive care medicine* 1995;21:606-9.
24. Choi SC, Narayan RK, Anderson RL, et al. Enhanced specificity of prognosis in severe head injury. *J Neurosurg* 1988;69:381-5.
25. Hsu MH, Li YC, Chiu WT, et al. Outcome prediction after moderate and severe head injury using an artificial neural network. *Stud Health Technol Inform* 2005;116:241-5.
26. Hukkelhoven CW, Steyerberg EW, Habbema JD, et al. Predicting outcome after traumatic brain injury: development and validation of a prognostic score based on admission characteristics. *J Neurotrauma* 2005;22:1025-39.
27. Murray GD, Butcher I, McHugh GS, et al. Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. *J Neurotrauma* 2007;24:329-37.
28. Perel P, Arango M, Clayton T, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. *BMJ* 2008;336:425-9.
29. Turgeon AF, Lauzier F, Burns KE, et al. Determination of neurologic prognosis and clinical decision making in adult patients with severe traumatic brain injury: a survey of Canadian intensivists, neurosurgeons, and neurologists. *Crit Care Med* 2013;41:1086-93.
30. Turgeon AF, Lauzier F, Scales DC, et al. Practice variation in the management and treatment of increased intracranial pressure in severe traumatic brain injury in Canada: a Canadian multicentre retrospective cohort study [abstract]. *Crit Care Med* 2009;37:A435.

- 1  
2  
3 31. Jennett B, Bond MR. Assessment of outcome after severe brain damage. *Lancet*  
4 1975;1:480-4.  
5  
6  
7 32. Jennett B, Snoek J, Bond M, et al. Disability after severe head injury: observations on the  
8 use of the Glasgow Outcome Scale. *J Neurol Neurosurg Psychiatry* 1981;44:285-93.  
9  
10 33. Tyson SF, Thomas N, Vail A, et al. Recruiting to inpatient-based rehabilitation trials: lessons  
11 learned. *Trials* 2015;16:588.  
12  
13 34. Fletcher B, Gheorghe A, Moore D, et al. Improving the recruitment activity of clinicians in  
14 randomised controlled trials: a systematic review. *BMJ open* 2012;2:e000496.  
15  
16 35. Dickson S, Logan J, Hagen S, et al. Reflecting on the methodological challenges of  
17 recruiting to a United Kingdom-wide, multi-centre, randomised controlled trial in  
18 gynaecology outpatient settings. *Trials* 2013;14:389.  
19  
20 36. Blanton S, Morris DM, Prettyman MG, et al. Lessons learned in participant recruitment and  
21 retention: the EXCITE trial. *Phys Ther* 2006;86:1520-33.  
22  
23 37. Gardner G, Gardner A, MacLellan L, et al. Reconceptualising the objectives of a pilot study  
24 for clinical research. *Int J Nurs Stud* 2003;40:719-24.  
25  
26 38. McIntyre LA, Fergusson D, Cook DJ, et al. Fluid resuscitation in the management of early  
27 septic shock (FINESS): a randomized controlled feasibility trial. *Can J Anaesth*  
28 2008;55:819-26.  
29  
30 39. Harrison DA, Prabhu G, Grieve R, Harvey SE, Sadique MZ, Gomes M, et al . Risk  
31 Adjustment In Neurocritical care (RAIN) – prospective validation of risk prediction models  
32 for adult patients with acute traumatic brain injury to use to evaluate the optimum location  
33 and comparative costs of neurocritical care: a cohort study. *Health Technol*  
34 *Assess* 2013;17 (23).  
35  
36 40. Andrews PJ, Sinclair HL, Rodriguez A, et al. Hypothermia for Intracranial Hypertension after  
37 Traumatic Brain Injury. *N Engl J Med* 2015;373:2403-12.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 41. Wright DW, Yeatts SD, Silbergleit R, et al. Very early administration of progesterone for  
4 acute traumatic brain injury. *N Engl J Med* 2014;371:2457-66.  
5  
6  
7 42. Potter JE, McKinley S, Delaney A. Research participants' opinions of delayed consent for a  
8 randomised controlled trial of glucose control in intensive care. *Intensive care medicine*  
9 2013;39:472-80.  
10  
11  
12 43. Gamble C, Nadel S, Snape D, et al. What parents of children who have received emergency  
13 care think about deferring consent in randomised trials of emergency treatments: postal  
14 survey. *PloS one* 2012;7:e35982.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Figure 1. TBI-Prognosis test schedule

The arrows indicate the prescribed time frame to perform tests or take blood samples. The study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7. The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before or after the seventh day.

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

### Figure 2. Reasons for non-enrolment

SDM: Shared Decision Making

### Figure 3. Compliance to the scheduled test procedures

CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials



	ICU Day 1	ICU Day 2	ICU Day 3	ICU Day 4	ICU Day 5	ICU Day 6	ICU Day 7	ICU Day 8	ICU Day 9		
CT-scan (+/- 24 hrs)	←→		←→			←→					
Blood samples (biomarkers)	←→		←→							←→	
EEG, SSEP, MRI (+/- 48 hrs)					←→						

Figure 1. TBI-Prognosis test schedule. ++ The arrows indicate the prescribed time frame to perform tests or take blood samples. The study requested that CT-scans be done on day 1, 3, and 7, with the possibility to conduct the scans 24 hours prior or after the required date. Blood samples were drawn on day 1, 3 and 7. The EEG, SSEP and MRI tests were required on day 7 but could be obtained 48 hours before or after the seventh day. CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

173x77mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Reasons for non-enrolment.† SDM: Shared Decision Making

173x129mm (300 x 300 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. Compliance to the scheduled test procedures. CT-scan: Computed Tomography Scan; EEG: Electroencephalogram; ICU: Intensive Care Unit; MRI: Magnetic Resonance Imaging; SSEP: Somatosensory Evoked Potentials

173x107mm (300 x 300 DPI)

view only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1, 4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7,8, Figure 1
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	Part of pilot goal
		(d) If applicable, explain how loss to follow-up was addressed	Part of pilot goal
		(e) Describe any sensitivity analyses	NA
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9, Figure 2
		(c) Consider use of a flow diagram	No
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	10, 11
		(c) Summarise follow-up time (eg, average and total amount)	11
Outcome data	15*	Report numbers of outcome events or summary measures over time	9, 10, 11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9, 10, 11
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11, 12
<b>Limitations</b>			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	5, 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12, 13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).